المؤلفون: A. Pchelintseva O., A. Zhornyak P., N. Ionichenok G., E. Panasyuk Yu., A. Ilyina E., I. Andrianova A., E. Gubar E., E. Tsvetkova S., M. Cherkasova V., E. Aleksandrova N., L. Denisov N., E. Nasonov L., А. Пчелинцева О., А. Жорняк П., Н. Иониченок Г., Е. Панасюк Ю., А. Ильина Е., И. Андрианова А., Е. Губарь Е., Е. Цветкова С., М. Черкасова В., Е. Александрова Н., Л. Денисов Н., Е. Насонов Л.

المصدر: Rheumatology Science and Practice; Vol 53, No 4 (2015); 379-384 ; Научно-практическая ревматология; Vol 53, No 4 (2015); 379-384 ; 1995-4492 ; 1995-4484 ; 10.14412/rsp20154

مصطلحات موضوعية: calprotectin, erythrocyte sedimentation rate, C-reactive protein level, rheumatoid arthritis, etanercept, DAS28, ACR 20/50/70, кальпротектин, СОЭ, уровень С-реактивного белка, ревматоидный артрит, этанерцепт

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/2108/1336; Александрова ЕН, Новиков АА, Насонов ЕЛ. Роль лабораторных биомаркеров в оценке эффективности терапии ревматоидного артрита генно-инженерными биологическими препаратами. В кн.: Генно-инженерные биологические препараты в лечении ревматоидного артрита. Насонов ЕЛ, редактор. Москва: ИМА-ПРЕСС; 2013. С. 101–22 [Aleksandrova EN, Novikov AA, Nasonov EL. The role of laboratory biomarkers in assessing the effectiveness of the treatment of rheumatoid arthritis genetically engineered biological agents. In: Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Nasonov EL, editor. Moscow: IMA-PRESS; 2013. P. 101–22].; Ehrchen JM, Sunderkö tter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86(3):557–66. doi:10.1189/jlb.1008647; Hsu K, Champaiboon C, Guenther BD, et al. Anti-infective protective properties of S100 calgranulins. Antiinflamm Antiallergy Agents Med Chem. 2009;8(4):290–305. doi:10.2174/187152309789838975; Chan JK, Roth J, Oppenheim JJ, et al. Alarmins: awaiting a clinical response. J Clin Invest. 2012;122(8):2711–9. doi:10.1172/JCI62423; Kane D, Roth J, Frosch M, et al. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum. 2003;48(6):1676–85. doi:10.1002/art.10988; Brun JG, Cuida M, Jacobsen H, et al. Sjö gren's syndrome in inflammatory rheumatic diseases: analysis of the leukocyte protein calprotectin in plasma and saliva. Scand J Rheumatol. 1994;23(3):114–8. doi:10.3109/03009749409103041; Van Bon L, Cossu M, Loof A, et al. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype. Ann Rheum Dis. 2014;73(8):1585–9. doi:10.1136/annrheumdis-2013-205013; Jung SY, Park YB, Ha YJ, et al. Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease. J Rheumatol. 2010;37(5):1029–34. doi:10.3899/jrheum.091120; Haga HJ, Brun JG, Berntzen HB, et al. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus. 1993;2(1):47–50.; Soyfoo MS, Roth J, Vogl T, et al. Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus. J Rheumatol. 2009;36(10):2190–4. doi:10.3899/jrheum.081302; Pepper RJ, Hamour S, Chavele KM, et al. Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCAassociated vasculitis and glomerulonephritis. Kidney Int. 2013;83(6):1150–8. doi:10.1038/ki.2013.2; Aochi S, Tsuji K, Sakaguchi M, et al. Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. J Amer Acad Dermatol. 2011;64(5): 879–87. doi:10.1016/j.jaad.2010.02.049; Kerkhoff C, Voss A, Scholzen TE, et al. Novel insights into the role of S100A8/A9 in skin biology. Exp Dermatol. 2012;21(11):822–6. doi:10.1111/j.1600-0625.2012.01571.x; Van Rheenen PF, van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;15(341):3369. doi:10.1136/bmj.c3369; Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn’s disease. Gut. 2000;47(4):506–13. doi:10.1136/gut.47.4.506; Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation. 2006;113(19):2278–84. doi:10.1161/CIRCULATIONAHA. 105.607333; Morrow DA, Wang Y, Croce K, et al. Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction (PROVE IT-TIMI 22) trial. Am Heart J. 2008;155(1):49–55. doi:10.1016/j.ahj.2007.08.018; Peng WH, Jian WX, Li HL, et al. Increased serum myeloid-related protein 8/14 level is associated with atherosclerosis in type 2 diabetic patients. Cardiovasc Diabetol. 2011 May 18;10:41. doi:10.1186/1475-2840-10-41; Malemud CJ. Myeloid-related protein activity in rheumatoid arthritis. Int J Inflam. 2011;2011:580295. doi:10.4061/2011/580295. Epub 2011 Aug 15.; Berntzen HB, Olmez U, Fagerhol MK, Munthe E. The leukocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol. 1991;20(2):74–82. doi:10.3109/03009749109165280; Brun JG, Haga HJ, Boe E, et al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol. 1992;19(6):859–62.; Youssef P, Roth J, Frosch M, et al. Expression of m eloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol. 1999;26(12):2523–8.; Baillet A, Trocme C, Berthier S, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford). 2010;49(4):671–82. doi:10.1093/rheumatology/ kep452; Пчелинцева АО, Панасюк ЕЮ, Рябицева ОФ и др. Эффективность этанерцепта у больных ревматоидным артритом (результаты российского многоцентрового исследования ЭТАЛОН). Научно-практическая ревматология. 2013;51(6):639–45 [Pchelintseva AO, Panasyuk EYu, Ryabitseva OF, et al. Efficacy of etanercept in patients with rheumatoid arthritis (results of the Russian multicenter ETALON study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):639–45]. doi:10.14412/1995-4484-2013-639-45; Madland TM, Hordvik M, Haga HJ, et al. Leukocyte protein calprotectin and outcome in rheumatoid arthritis. A longitudinal study. Scand J Rheumatol. 2002;31(6):351–4. doi:10.1080/030097402320817077; Garcia-Arias M, Pascual-Salcedo D, Ramiro S, et al. Calprotectin in rheumatoid arthritis: association with disease activity in a crosssectional and a longitudinal cohort. Mol Diagn Ther. 2013;17(1):49–56. doi:10.1007/s40291-013-0016-9; Andres Cerezo L, Mann H, Pecha O, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther. 2011;13(4):R122. doi:10.1186/ar3426; Choi IY, Gerlag DM, Holzinger D, et al. From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis. PLoS One. 2014;9(8):e106253. doi:10.1371/journal.pone.0106253; Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13(5):R178. doi:10.1186/ar3503; Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis. 2007;66(8):1093–7. doi:10.1136/ard.2006.064741; Hammer HB, Odegard S, Syversen SW, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis. 2010;69(1):150–4. doi:10.1136/ard.2008.103739; Obry A, Lequerre T, Hardouin J, et al. Identification of s100a9 as biomarker of responsiveness to the methotrexate/etanercept combination in rheumatoid arthritis using a proteomic approach. PLoS One. 2014;9(12):e115800. doi:10.1371/journal.pone.0115800; Choi IY, Gerlag DM, Herenius MJ, et al. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74(3):499–505. doi:10.1136/annrheumdis-2013-203923; Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015;42:5. doi:10.3899/jrheum.140628; https://rsp.mediar-press.net/rsp/article/view/2108

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/2108
https://doi.org/10.14412/1995-4484-2015-379-384

المؤلفون: Anna Pchelintseva Olegovna, E Panasyuk Yu, O Ryabitseva F, V Mazurov I, I Salikhov G, A Sizikov E, O Ivanova N, V Sorotskaya N, O Semagina V, I Vinogradova V, A Kulikov I, L Denisov N, E Nasonov L, Е. Панасюк Ю., В. Мазуров И., И. Салихов Г., В. Сороцкая Н., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 51, No 6 (2013); 639-45 ; Научно-практическая ревматология; Vol 51, No 6 (2013); 639-45 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-6

مصطلحات موضوعية: rheumatoid arthritis, Etanercept, DAS28, ACR20/50/70, SDAI, CDAI, ревматоидный артрит, этанерцепт

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1346/1006; https://rsp.mediar-press.net/rsp/article/view/1346

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1346
https://doi.org/10.14412/1995-4484-2013-639-45

المؤلفون: E Nasonov L, E Aleksandrova N, A Avdeeva S, E Panasyuk Yu, Евгений Насонов Львович, Елена Александрова Николаевна, Е. Панасюк Ю.

المصدر: Rheumatology Science and Practice; Vol 51, No 4 (2013); 416-427 ; Научно-практическая ревматология; Vol 51, No 4 (2013); 416-427 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-4

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1155/827; Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16. McInnes I.B., Shett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19. Новиков А.А., Александрова Е.Н., Диатроптова М.А., Насонов Е.Л. Роль цитокинов в патогенезе ревматоидного артрита. Науч-практич ревматол 2010;2:71-82. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Под ред. Е.Л. Насонова. М.: ИМА-ПРЕСС, 2013;549 с. Heinrich P.C., Behrmann I., Haan S. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374(Pt 1):1-20. Jones S.A., Richards PJ., Scheller J., Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005;25:241-53. Mihara M., Hashizume M., Yoshida H. et al. IL6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci 2012;122;143—59. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54. Andrews N.C. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004;113:1251-3. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332:1351-62. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010;49:15-24. Hashizume M., Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011;2011:765624. doi:10.1155/2011/765624. Edwards C.J., Williams E. The role of interleukin 6 in rheumatoid arthritis. Osteoporosis Int 2010;13 Mаr [Epub ahead of print]. Kimursa A., Kishimoto T. IL6: regulator of T reg/Th17 balance. Eur J Immunol 2010;40:1830-5. Sato K., Tsuchiya M., Saldanha J. et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res 1993;53:851-6. Smolen J., Beaulieu A., Ruddert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomized trial. Lancet 2008;371:987-97. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80. Nishimoto N., Hashimoto J., Miaysaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. Nishimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9. Kremer J.L., Blanco R., Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year; the Lithe study. Arthr Rheum 2011;63:609-21. Emery P., Keystone E., Tony H.-P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96. Yazici Y., Curtis J.R., Ince A. et al. Efficacy of tocilizumab in patients with moderate to severe rheumatoid arthritis and previously inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2011 [Epub ahead of print]. Dougados M., Kissel K., Sheeran T. et al. Adding tocilizumab or switching to tociluzumab monotherapy in methotrexate inadequate responders: 24-week symtomatic and structural results od a 2-year randomized controlled strategy trial in rheumatoid arthritis (ACT-RAY) Ann Rheum Dis 2012 [Epub ahead of print]. Bykerk V., Ostor A., Alvaro-Gracia J. et al. Tocilizumab in patients with active rheumatoid arthritis and an inadequate response to DMARDs and/or the TNF inhibitor therapy: a large open-label study close to clinical precice Ann Rheum Dis 2012 [Epub ahead of print]. Bykerk V., Ostor A., Ivora J.A.R. et al. Comparison of tocilizum-ab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and an inadequate response to previous treatments. Arthr Rheum 2011;63(Suppl):S866. Weinblatt E., Kremer J.M., Cush J.J. et al. Tocilizumab monotherapy and tocilizumab plus disease-modifying antirheumatic drugs in a US Rheumatoid Arthritis population with inadequate response to amti-tumor necrosis factor agents. Arthr Rheum 2011;63(Suppl):S162. Burmester G.R., Feist E., Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with avtive rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9. Панасюк Е.Ю., Амирджанова В.Н., Авдеева А.С., Лучихина Е.Л., Александрова Е.Н., Новиков А.А., Насонов Е.Л. и представители исследовательских центров. Опыт применения тоцилизумаба у больных ревматоидным артритом (по данным многоцентрового исследования ЛОРНЕТ). Науч-практич ревматол 2013;51:104-10. Smolen J., Martinez-Avila J., Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: dissociation of the linl between inflammation and destruction. Ann Rheum Dis 2011 [Epub ahead of print]. Nishimto N., Ito K., Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010 [Epub ahead of print]. Mao Mao An, Zui Zou, Hei Shen et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010 [Epub ahead of print]. Singh J.A., Beg S., Lopez-Olivo M.A. Tocilizumab for rheumatoid arthritis: a Cochrane systemic review. J Rheumatol 2010 [Epub ahead of print]. Schoels M., van der Heijde D., Breedveld F. et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systemic literature review and metaanalysis informing a consensus statement. Ann Rheum Dis 2012; Nov 12 [Epub ahead of print]. Smolen J.S., Schoels M.M., Nishimoto N. et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2012 [Epub ahead of print]. Shakib J., Sepehr F., Smith B. Safety, pharmacokinetics and pharmacodynamics of ALD518 (BMS-945429), a high-affinity monoclonal antibody directed against interleukin-6 (IL-6) administered by subcutaneous injection: a phase I trial. Arthr Rheum 2010;62(Suppl 10):1124. Mease P., Strand V., Shalamberidze L. et al. A phase II, doubleblind, randomized, placebо-controlled study of BMS945429 (ADL518) in patients with rheumatoid arthritis with an inadequate respose to methotrexate. Ann Rheum Dis 2012;Feb [Epub ahead of print]. Strand V., Shalamberidze L., Dimic A. et al. BMS-945429 (ALD518), a high-affinity anti-interleukin-6 monoclonal antibody, is associated with improvements in health-related quality of life in patients with rheumatoid arthritis and inadequate response to methotrexate. Ann Rheum Dis 2011;70(Suppl 3):621. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J Clin Invest 2003;112:978-80. ClinicalTrials.gov. Phase IIB rheumatoid arthritis dose ranging study for BMS-945429 in subjects who are not responding to methotrexate. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01373151 Sanofi and Regeneron report positive phase 2b trial results with sarilumab in rheumatoid arthritis [press release]. Paris, France and Tarrytown, NY: PR Newswire; July 12, 2011. Accessed 10/21/11 at: http://www.reuters.com/article/2011/07/12/idUS215877+12 Jul-2011+PRN20110712 Radin A.R., Mellis S.J., Jasson M. et al. REGN88/SAR153191, a fully-human interleukin-6 receptor monoclonal antibody, reduced acute phase reactants in patients with rheumatoid arthritis: preliminary observations from phase 1 studies. Arthr Rheum 2010; S1121 ClinicalTrials.gov. Evaluation of SAR153191 (REGN88) on top of methotrexate in rheumatoid arthritis patients (MOBILITY). 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01061736 ClinicalTrials.gov. Effect of SAR153191 (REGN88) with methotrexate in patients with active rheumatoid arthritis who failed TNF-а blockers. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01217814 ClinicalTrials.gov. Long term evaluation of SAR153191 (REGN88) on top of disease modifying anti-rheumatic drugs in rheumatoid arthritis patients (ABILITY). 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01146652 Xu Z., Bouman-Thio E., Comisar C. et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81. Hsu B., Zhou B., Smolen J.S., Weinblatt M.E. Proof-of-concept for CNTO 136, a human anti-interleukin-6 monoclonal antibody, in a multicenter, randomized, double-blind, placebo-controlled, phase 2 study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2011;70(Suppl 3):459. ClinicalTrials.gov. A study of the effectiveness and safety of CNTO 136 in patients with active rheumatoid arthritis despite methotrexate therapy. 2011. Accessed 10/21/11 at: http://clinicaltrials. gov/ct2/show/NCT00718718 Hickling M., Golor G., Jullion A. et al. Safety and pharmacokinetics of CDP6038, an anti-IL-6 monoclonal antibody, administered by subcutaneous injection and intravenous infusion to healthy male volunteers: a phase 1 study. Ann Rheum Dis 2011;70(Suppl 3):471. ClinicalTrials.gov. To evaluate the blood levels and safety of IV and subcutaneous CDP6038 in subjects with rheumatoid arthritis using methotrexate. 2010. Accessed 10/21/11 at: http://clinical-trials.gov/ct2/show/NCT01009242 ClinicalTrials.gov. Open-label study to assess the safety and efficacy of CDP6038 in patients who completed RA0056. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01296711 ClinicalTrials.gov. Efficacy and safety of CDP6038 in patients with rheumatoid arthritis with an unsuccessful response to antitumor necrosis factor (anti-TNF) therapy. 2011. Accessed 10/21/11 at: http://clinicaltrials.gov/ct2/show/NCT01242488 Mihara M., Takagi N., Takeda Y. et al. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998;112:397-402. Liang B., Gardner D.B., Griswold D.E. et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006;119:296-305. Pflegerl P., Vesely P., Hantusch B. et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci USA 2009;106:20423-8. Kitaba S., Murota H., Terao M. et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am J Pathol 2012;80:165-76. Yoshizaki A., Yanaba K., Ogawa A. et al. Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthr Rheum 2011;63:3575-85. Okiyama N., Sugihara T., Iwakura Y. et al. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthr Rheum 2009;60:2505-12. Woo P., Wilkinson N., Prieur A.M. et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthr Res Ther 2005;7:R1281-R1288. Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthr Rheum 2005;52:818-25. Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008;371:998-1006. De Benedetti F., Brunner H., Ruperto N. et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: efficacy data from the placebo-controlled 12-week part of the phase 3 TENDER trial. Arthr Rheum 2010;62(Suppl 10):1434. De Benedetti F., Brunner H., Ruperto N. et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data. Pediat Rheumatol 2011;9(Suppl 1):164. Illei G.G., Shirota Y., Yarboro C.H. et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthr Rheum 2010;62:542-52. Maeshima K., Ishii K., Torigoe M. et al. Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus. Lupus 2012 [Epub ahead of print]. Makol A., Gibson L.E., Michet C.J. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol 2012;18:92-5. Shima Y., Kuwahara Y., Murota H. et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatology (Oxford) 2010;49:2408-12. Elhai M., Meunier M., Matucci-Cerinic M. et al. Outcome of patients with systemic sclerosic-associqted polyarthritis and myopathy treated with tocilizumab or abatacept; a EUSTAR observational study. Ann Rheum Dis 2012, Dec 19[Epub ahead of print]. Narazaki M., Hagihara K., Shima Y. et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 2011;50:1344-6. Seitz M., Reichenbach S., Bonel H.M. et al. Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 2011;141:w13156. Beyer C., Axmann R., Sahinbegovic E. et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis. Ann Rheum Dis 2011;70:1874-5. Sciascia S., Rossi D., Roccatello D. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis. J Rheumatol 2011;38:2080-1. Salvarani C., Magnani L., Catanoso M. et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012;51:151-6. Vinit J., Bielefeld P., Muller G. et al. Efficacy of tocilizumab in refractory giant cell arteritis. Joint Bone Spine 2012;79:317-8. Christidis D., Jain S., Das Gupta B. Successful use of tocilizumab in polymyalgic onset biopsy positive GCA with large vessel involvement. BMJ Case Reports 2011 [Epub ahead of print]. Nishimoto N., Nakahara H., Yoshio-Hoshino N. et al. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthr Rheum 2008;58:1197-200. Salvarani C., Magnani L., Catanoso M.G. et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-а blockers. Clin Exp Rheumatol 2012 [Epub ahead of print]. Bredemeier M., Rocha C.M., Barbosa M.V. et al. One-year clinical and radiological evolution of a patient with refractory Takayasu’s arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012 [Epub ahead of print]. Cohen C., Mekinian A., Saidenberg-Kermanach N. et al. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Ann Rheum Dis 2012;71:628-9. Sumida K., Ubara Y., Suwabe T. et al. Complete remission of myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis complicated with rheumatoid arthritis using a humanized anti-interleukin 6 receptor antibody. Rheumatology (Oxford) 2011;50:1928-30. Sumida K., Ubara Y., Takemoto F. et al. Successful treatment with humanized anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin Exp Rheumatol 2011;29 (1 Suppl 64):S133. Hagihara K., Kawase I., Tanaka T. et al. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 2010;37:1075-6. Kawai M., Hagihara K., Hirano T. et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford) 2009;48:318-9. Narshi C.B., Allard S.A. Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-? failure in a patient with relapsing polychondritis complicated by aortitis. Rheumatology (Oxford) 2012;51:952-3. Iwamoto M., Nara H., Hirata D. et al. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still’s disease. Arthr Rheum 2002;46:3388-9. Nakahara H., Mima T., Yoshino-Hoshino N. et al. A case report of a patient with refractory adult-onset Still’s disease who was successfully treated with tocilizumab over 6 years. Mod Rheumatol 2009;19:69-72. De Bandt M., Saint-Marcoux B. Tocilizumab for multirefractory adult-onset Still's disease. Ann Rheum Dis 2009;68:153-4. Matsumoto K., Nagashima T., Takatori S. et al. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 2009;28:485-7. Cunha M.L., Wagner J., Osawa A. et al. The effect of tocilizum-ab on the uptake of 18FDG-PET imaging in patients with adult-onset Still’s disease. Rheumatology (Oxford) 2010;49:1014-6. Sumida K., Ubara Y., Hoshino J. et al. Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab. Clin Rheumatol 2010;29:1191-4. Yoshimura M., Makiyama J., Koga T. et al. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD) Clin Exp Rheumatol 2010;28:141-2. Perdan-Pirkmajer K., Praprotnik S., Tomsic M. A case of refractory adult-onset Still’s disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 2010;29:1465-7. Naniwa T., Ito R., Watanabe M. et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still’s disease. Clin Rheumatol 2010 [Epub ahead of print]. Kishida D., Okuda Y., Ohnishi M. et al. Successful tocilizumab treatment in a patient with adult-onset Still’s disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol 2011;21:215-8. Thonhofer R., Hiller M., Just H. et al. Treatment of refractory adult-onset Still’s disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 2011;31:1653-6. Sabnis G.R., Gokhale Y.A., Kulkarni U.P. Tocilizumab in refractory adult-onset Still’s disease with aseptic meningitis-efficacy of interleukin-6 blockade and review of the literature. Semin Arthr Rheum 2011;40:365-8. Rech J., Ronneberger M., Englbrecht M. et al. Successful treatment of adult-onset Still’s disease refractory to TNF and IL-1 blockade by IL-6 blockade. Ann Rheum Dis 2011;70:390-2. Kobayashi M., Takahashi Y., Yamashita H. et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol 2011;21:92-6. Puechal X., DeBandt M., Berthelot J.M. et al. Tocilizumab in refractory adult Still’s disease. Arthr Care Res 2011;63:155-9. Sekkach Y., Elqatni M., Khattabi A.E. et al. Antagonists of interleukin-6 (tocilizumab), in adult refractory still disease. Presse Med 2011;40:e333—7. Suematsu R., Ohta A., Matsuura E. et al. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol 2011 [Epub ahead of print]. Okuda Y., Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthr Rheum 2006;54:2997-3000. Nishida S., Hagihara K., Shima Y. et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009;68:1235-6. Sato H., Sakai T., Sugaya T. et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2009;28:1113-6. Inoue D., Arima H., Kawanami C. et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis. Clin Rheumatol 2010;29:1195-7. De la Torre M., Arboleya L., Pozo S. et al. Rapid and sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in a patient with nephritic syndrome secondary to systemic juvenile idiopathic arthritis-related amyloidosis. NDT Plus 2011;4:178-80. Magro-Checa C., Navas-Parejo Casado A., Borrego-Garcia E. et al. Successful use of tocilizumab in a patient with nephritic syndrome due to a rapidly progressing AA amyloidosis to latent tuberculosis. Amyloid 2011;18:235-9. Hattori Y., Ubara Y., Sumida K. et al. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis. Amyloid 2012;19:37-40. Ogata A., Umegaki N., Katayama I. et al. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012;79:85-7. Hughes M., Chinoy H. Succesful use of tocilizumab in a patients with psoriatic arthritis. Rheumatology (Oxford) 2013; Feb 18 [Epub ahead of print]. Tanaka T., Kuwahara Y., Shima Y. et al. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Arthr Rheum 2009;61:1762-4. Henes J.C., Horger M., Guenaydin I. et al. Mixed response to tocilizumab for ankylosing spondylitis. Ann Rheum Dis 2010;69:2217-8. Wendling D., Bossert M., Prati C. Short-term effect of IL-6 inhibition in spondylarthritis. Joint Bone Spine 2010;77:624-5. Brulhart L., Nissen M.J., Chevallier P. et al. Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists. Joint Bone Spine 2010;77:625-6. Shima Y., Tomita T., Ishii T. et al. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis. Mod Rheumatol 2011;21:436-9. Cohen J.D., Ferreira R., Jorgensen C. Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab. J Rheumatol 2011;38:1527. Koumakis E., Feydy A., Kahan A. et al. Interleukin 6 blockade in spondyloarthritis. J Rheumatol 2012;39:1097-8. Sieper J., Porter-Brown B., Thompson L. et al. Assesment of short-term symptomatic efficacy of tocilizumab in ankylosing spondilitis: results of randomised, placebo-controlled trials. Ann Reum Dis 2013; June 13 [Epub ahead of print]. Lekpa F.K., Poulain C., Wendling D. et al. Is IL-6 an appropriate target to treatment spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthr Res Ther 2012;14:R53. Hirano T., Ohguro N., Hohki S. et al. A case of Behcet’s disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012;22:298-302. Shapiro L.S., Farrell J., Haghighi A.B. Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clin Neurol Neurosurg 2011;114:297-8. Diamantopoulos A.P., Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet’s syndrome: report of two cases. Rheumatology (Oxford) 2013;Apr 4 [Epub ahead of print]. Pinto J.L., Mora G.E. Fernandez-Avila D.G. et al. Tocilizumab in a patients with tophaceous gout resistant to treatment. Rheumatol Clin 2013;9:178-80. Tsokos G.C. Systemic lupus erythematosus. New Engl J Med 2011;365:2110-21. Shin M.S., Lee N., Kang I. Effector T-cell subsets in systemic lupus erythematosus: update focusing on Th17 cells. Curr Opin in Rheumatol 2011;5:444-8. Obermoser G., Pascual V. The interferon-а signature of systemic lupus erythematosus. Lupus 2010;19;1012—9. Rhodes B., Furnrohr B.G., Vyse T.J. C-reactive protein in rheumatology: biology and genetics. Nat Revi Rheumatol 2011;7:282-9. Tackey E., Lipsky P.E., Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-43. Linker-Israeli M., Deans R.J., Wallace D.J. et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991;147:117-23. Peterson E., Robertson A.D., Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 1996;5:571-5. Grondal G., Gunnarsson I., Ronnelid J. et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18;565—70. Iwano M., Dohi K., Hirata E. et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol 1993;40:16-21. Malide D., Russo P., Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Human Pathol 1995;26:558-64. Herrera-Esparza R., Barbosa-Cisneros O.V., Illalobos-Hurtado R., Avalos-Diaz E. Renal expression of IL-6 and TNFα genes in lupus nephritis. Lupus 1998;7:154-8. Tsai G.Y., Wu T.H., Yu C.L. et al. Increased excretions of β2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 2000;85:207-14. Hirohata S., Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthr Rheum 1990;33:644-9. Hagiwara E., Gourley M.F., Lee S., Klinman D.M. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: interferon-γ-secreting cells in the peripheral blood. Arthr Rheum 1996;39:379-85. Swaak G., van den Brink H.G., Aarden L.A. Cytokine production (IL-6 and TNFα) in whole blood cell cultures of patients with systemic lupus erythematosus. Scand J Rheumatol 1996;25:233-8. Klashman D.J., Martin R.A., Martinez-Maza O., Stevens R.H. In vitro regulation of B cell differentiation by interleukin-6 and soluble CD23 in systemic lupus erythematosus B cell subpopulations and antigen-induced normal B cells. Arthr Rheum 1991;34:276-86. Kitani A., Hara M., Hirose T. et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immun 1992;88:75-83. Suzuki H., Yasukawa K., Saito T. et al. Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993;23:1078-82. Tang B., Matsuda T., Akira S. et al. Age-associated increase in interleukin 6 in MRL/lpr mice. Int Immunol 1991;3:273-8. Alarcon-Riquelme M.E., Moller G., Fernandez C. Age-dependent responsiveness to interleukin-6 in B lymphocytes from a systemic lupus erythematosus-prone (NZB x NZW)F1 hybrid. Clin Immunol Immunopath 1992;62:264-9. Mihara M., Fukui H., Koishihara Y. et al. Immunologic abnormality in NZB/W F1 mice. Thymus-independent expansion of B cells responding to interleukin-6. Clin Exp Immunol 1990;82:533-7. Mihara M., Ohsug Y. Possible role of IL-6 in pathogenesis of immune complex-mediated glomerulonephritis in NZB/W F1 mice: induction of IgG class anti-DNA autoantibody production. Intern Arch Allergy Appl Immunol 1990;93:89-92. Ryffel B., Car B.D., Gunn H. et al. Interleukin-6 exacerbates glomerulonephritis in (NZBxNZW)F1 mice. Amer J Pathol 1994;144:927-37. Finck B.K., Chan B., Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Inves 1994;94:585-91. Mihara M., Takagi N., Takeda Y., Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/WF1 mice. Clin Exp Immunol 1998;112:397-402. Liang B., Gardner D.B., Griswold D.E. et al. Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus. Immunology 2006;119:296-305. Pflegerl P., Vesely P., Hantusch B. et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc Natl Acad Sci USA 2009;106:20423-8. Gabrielli A., Avvedimento E.V., Krieg T. Mechanisms of disease: Scleroderma. New Engl J Med 2009;360:1989-2003. Barnes T.C., Anderson M.E., Moots R.J. The many faces of interleukin-6 (IL-6): the role of IL-6 in inflammation, vasculopathy and fibrosis in systemic sclerosis. Int J Rheumatol 2011;2011:Article ID 721608. Muangchan C., Pope J.E. Interleukin 6 in systemic sclerosis and potential implications for targeted therapy. J Rheumatol 2012;39:1120-4. Needleman B.W., Wigley F.M., Stair R.W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthr Rheum 1992;35:67-72. Koch A.E., Kronfeld-Harrington L.B., Szekanecz Z. et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease. Pathobiology 1993;61:239-46. Stuart R.A., Littlewood A.J., Maddison PJ., Hall N.D. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995;13:17-22. Hasegawa M., Sato S., Fujimoto M. et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998;25:308-13. Sato S., Hasegawa M., Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140-6. Scala E., Pallotta S., Frezzolini A. et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004;138:540-6. Matsushita T., Hasegawa M., Hamaguchi Y. et al. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006;33:275-84. Nihtyanova S., Black C.M., Denton C.P. A clinically defined subset of dcSSc is associated with elevated serum IL-6 level [abstract]. Arthr Rheum 2009;60(Suppl):440. Gourh P., Arnett F.C., Assassi S. et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthr Res Ther 2009;11:R147. Pope J., Harding S., Khimdas S. et al. C-reactive protein is associated with high disease activity in SSc. Results from the Canadian Scleroderma Research Group (CSRG) [abstract]. Arthr Rheum 2009;60(Suppl):471. Аігуєгпіпі S., De Santis M., Tolusso B. et al. Skin ulcers in systemic sclerosis: Determinants of presence and predictive factors of healing. J Am Acad Dermatol 2009;60:426-35. Feghali C.A., Bost K.L., Boulware D.W., Levy L.S. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992;19:1207-11. Feghali C.A., Bost K.L., Boulware D.W., Levy L.S. Control of IL-6 expression and response in fibroblasts from patients with systemic sclerosis. Autoimmunity 1994;17:309-18. Zurita-Salinas C., Richaud-Patin Y., Krötzsch-Gömez E. et al. Spontaneous cytokine gene expression by cultured skin fibroblasts of systemic sclerosis. Correlation with collagen synthesis. Rev Invest Clin 1998;50:97-104. Yamamoto T., Katayama I., Nishioka K. Fibroblast proliferation by bleomycin stimulated peripheral blood mononuclear cell factors. J Rheumatol 1999;26:609-15. Kawaguchi Y., Harigai M., Suzuki K. et al. Interleukin 1 receptor on fibroblasts from systemic sclerosis patients induces excessive functional responses to interleukin 1 beta. Biochem Biophys Res Commun 1993;190:154-61. Takemura H., Suzuki H., Fujisawa H. et al. Enhanced interleukin 6 production by cultured fibroblasts from patients with systemic sclerosis in response to platelet derived growth factor. J Rheumatol 1998;25:1534-9. Kadono T., Kikuchi K., Ihn H. et al. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998;25:296-301. Kawaguchi Y., Hara M., Wright T.M. Endogenous IL-1-alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999;103:1253-60. Kawaguchi Y., McCarthy S.A., Watkins C., Wright T.M. Autocrine activation by interleukin 1-alpha induces the fibrogenic phenotype of systemic sclerosis fibroblasts. J Rheumatol 2004;31:1946-54. Fukasawa C., Kawaguchi Y., Harigai M. et al. Increased CD40 expression in skin fibroblasts from patients with systemic sclerosis (SSc): Role of CD40-CD154 in the phenotype of SSc fibroblasts. Eur J Immunol 2003;33:2792-800. Kawai M., Masuda A., Kuwana M. A CD40-CD154 interaction in tissue fibrosis. Arthr Rheum 2008;58:3562-73. Aqache I., Radoi M., Duca L. Platelet activation in patients with systemic scleroderma-pattern and significance. Rom J Intern Med 2007;45:183-91. Kondo K., Okada T., Matsui T. et al. Establishment and characterization of a human B cell line from the lung tissue of a patient with scleroderma; extraordinary high level of IL-6 secretion by stimulated fibroblasts. Cytokine 2001;13:220-6. Crestani B., Seta N., De Bandt M. et al. Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 1994;149:1260-5. Giacomelli R., Cipriani P., Danese C. et al. Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. J Rheumatol 1996;23:291-6. Gurram M., Pahwa S., Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mononuclear cells from patients with systemic sclerosis. Ann Allergy 1994;73:493-6. Hasegawa M., Sato S., Ihn H., Takehara K. Enhanced production of interleukin-6 (IL-6), oncostatin M and soluble IL-6 receptor by cultured peripheral blood mononuclear cells from patients with systemic sclerosis. Rheumatology 1999;38:612-7. Barnes T.C., Spiller D.G., Anderson M.E. et al. Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signaling: A novel target for systemic sclerosis? Ann Rheum Dis 2011;70:366-72. Dalakas M.C. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010;10:346-52. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 2008;88:1379-1406. Carson J.A., Baltgalvis K.A. Interleukin 6 as a key regulator of muscle mass during cachexia. Exercise Sport Sci Rev 2010;38:168-76. Gabay С., Gay-Croisier F., Roux-Lombard P. et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthr Rheum 1994;37:1744-51. Lundberg I., Ulfgren A.K., Nyberg P. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthr Rheum 1997;40:865-74. Lepidi H., Frances V., Figarella-Branger D. et al. Local expression of cytokines in idiopathic inflammatory myopathies. Neur Appl Neurobiol 1998;24:73-9. Okada M., Kitahara M., Kishimoto S. et al. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988;141:1543-9. Bilgic H., Ytterberg S.R., Amin S. Interleukin-6 and type I interferon-regulated genes and chemokines Mark disease activity in dermatomyositis. Arthr Rheum 2009;60:3436-46. Scuderi F., Mannella F., Marino M. et al. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmun 2006;176:9-15. Okiyama N., Sugihara T., Iwakura Y. et al. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthr Rheum 2009;60:2505-12. Noris M., Daina E., Gamba S. et al. Interleukin-6 and RANTES in Takayasu arteritis a guide for therapeutic decisions? Circulation 1999;100:55-60. Park M.C., Lee S.W., Park Y.B., Lee S.K. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis. Rheumatology (Oxford) 2006;45:545-8. Garcia-Martinеz A., Hernandez-Rodrigues J., Espigol-Frigole G. et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor а and interleukin-6) in the long-term followup of patients with giant cell arteriitis. Arthr Care Res (Hoboken) 2010;62:835-41. Martinez-Taboada V.M., Alvarez L., Ruiz Soto M. et al. Giant cell arteriitis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008;44:207-20. Deng J., Younge B.R., Olshen R.A. et al. Th17 and Th1 T cell responses in giant cell arteriitis. Circulation 2010;121:906-15. Espigol-Frigole G., Corbera-Bellalta M., Planas-Rigol E. et al. Incresed IL-17 expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 2012;Sep 19 [Epub ahead of print]. Hernandez-Rodriquez J., Segarra M., Vilardell C. et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 2003;107:2428-34. Nakahama H., Okada M., Miyazaki M. et al. Distinct responses of interleukin-6 and other laboratory parameters to treatment in a patient with polyarteritis nodosa: a case report. Angiology 1992;43:512-6. Muller Kobold A.C., van Wijk R.T., Franssen C.F.M. et al. In vitro up-regulation of E-selectin and induction of interleukin-6 in endothelial cells by autoantibodies in Wegener’s granulomatosis and microscopic polyangiitis. Clin Exp Rheumatol 1999;17:433-40 Popa E.R., Franssen C.F.M., Limburg P.C. et al. In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthr Rheum 2002;46:1894-904; https://rsp.mediar-press.net/rsp/article/view/1155

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1155
https://doi.org/10.14412/1995-4484-2013-1254

المؤلفون: Rita Osipyants Aleksandrovna, D Karateev E, E Panasyuk Yu, G Lukina V, A Smirnov V, S Glukhova I, E Aleksandrova N, A Volkov V, E Nasonov L, Р. Осипянц А., Дмитрий Каратеев Евгеньевич, Е. Панасюк Ю., Г. Лукина В., А. Смирнов В., С. Глухова И., Елена Александрова Николаевна, А. Волков В., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 51, No 5 (2013); 500-506 ; Научно-практическая ревматология; Vol 51, No 5 (2013); 500-506 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-5

مصطلحات موضوعية: rheumatoid arthritis remission, joint ultrasonography, subclinical synovitis, X-ray destruction progression, tocilizumab, ремиссия ревматоидного артрита, ультразвуковое исследование суставов, субклинический синовит, рентгенологическое прогрессирование деструкции, тоцилизумаб

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1335/995; Ревматология: Национальное руководство. Насонова ЕЛ, Насонова ВА. Москва: ГЭОТАР-Медиа; 2008. 296. [Revmatologiya: Natsional'noe rukovodstvo. Nasonova EL, Nasonova VA. Moscow: GEOTAR-Media; 2008. 296.] Pap T, Distler O. Linking angiogenesis to bone of destruction in arthritis. Arthritis Rheum. 2005;52(5):1346–8. DOI: http://dx.doi.org/10.1002%2Fart.21015. Puolakka K, Kautiainen H, Mottonen T et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of the work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum. 2004;50(1):55–62. DOI: http://dx.doi.org/10.1002%2Fart.11436. Каратеев ДЕ, Лучихина ЕЛ. Современные принципы лечения ревматоидного артрита: акцент на раннюю агрессивную терапию. Эффективная фармакотерапия. 2011;1:12–7. [Karateev DE, Luchikhina EL. Sovremennye printsipy lecheniya revmatoidnogo artrita: aktsent na rannyuyu agressivnuyu terapiyu. Effektivnaya farmakoterapiya. 2011;1:12–7.] Smolen J, Landewe R, Breedveld F et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75. DOI:10.1136/ard.2009.126532. Epub 2010 May 5. Brown AK, Quinn MA, Karim Z et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54(12):3761–73. DOI:10.1002%2Fart.22190. Balsa A, de Miguel E, Castillo C et al. Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard. Rheumatology (Oxford). 2010;49(4):683-90. DOI:10.1093/rheumatology/kep442. Epub 2010 Jan 4. Ma M, Scott I, Kingsley H et al. Remission in Early Rheumatoid Arthritis. J Rheumatol 2010;37(7):1444–53. Taylor P, Steuer A, Gruber J et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of Infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. 2004;50(4):1107–16. DOI: http://dx.doi.org/10.1002%2Fart.20123. Jimenez-Boj E, Nobauer-Huhmann I, Hanslik-Schnabel B et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthritis Rheum. 2007;56(4):1118–24. DOI: http://dx.doi.org/10.1002%2Fart.22496. Fukae J, Isobe M, Kitano A et al. Radiographic prognosis of finger joint damage predicted by early alteration in synovial vascularity in patients with rheumatoid arthritis: potential utility of power Doppler sonography in clinical practice. Arthritis Care Res (Hoboken) 2011;63(9):1247–53. DOI: http://dx.doi.org/10.1002%2Facr.20517 Brown AK, Conaghan PG, Karim Z et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 2008;58(10):2958–67. DOI:10.1002/art.23945. Foltz V, Gandjbakhch F, Etchepare F et al. Power Doppler but not low-field MRI predict relapse and radiographic disease progression in rheumatoid arthritis patients with low disease activity. Arthritis Rheum. 2012;64(1):67–76. DOI:10.1002/art.33312. Prevoo MLL, van Hoff MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joints counts. Arthritis Rheum. 1995;38(1):44–52. DOI: http://dx.doi.org/10.1002%2Fart.1780380107. Smolen J, Breedveld F, Schiff M et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42:244–57. DOI: http://dx.doi.org/10.1093%2Frheumatology%2Fkeg072. Kosinski M, Zhao SZ, Dedhiya S et al. Determing minimally important changes in general and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arhtritis Rheum. 2000;43(7):1478–87. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261–3. Wakefield RJ, Balint PV, Szkudlarek M et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol. 2005;32(12):2485–7. Peluso G, Michelutti A, Bosello S et al. Clinical and ultrasonographic remission determines different chances of relapse in early and long standing rheumatoid arthritis. Ann Rheum Dis. 2011;70(1):172–5. DOI:10.1136/ard.2010.129924. Epub 2010 Nov 19. Aletaha D, Ward M, Machold K et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum. 2005;52(9):2625–36. Wakefield R, D’Agostino MA, Naredo E et al. After treat-to target: can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis. 2012;71(6):799–803. DOI:10.1136/annrheumdis-2011-201048. Epub 2012 May 5. Jacobsson L, Hetland M. New remission criteria for RA: «modern times» in rheumatology not a silent film, rather a 3D movie. Ann Rheum Dis. 2011;70(3):401–3. DOI:10.1136/ard.2010.145607. Saleem B, Brown A, Keen H et al. Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments. Ann Rheum Dis. 2011;70(5):792–8. DOI:10.1136/ard.2010.134445. Epub 2011 Jan 17. Townes S, Furst D, Thenkondar A et al. The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systemic literature review and interpretation. Open Access Rheumatology: Research and Reviews. 2012;4:87–92. Smolen J, Aletaha D, Bijsma J et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):613–7. DOI:10.1136/ard.2009.123919. Epub 2010 Mar 9. Saleem B, Brown A, Keen H et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs. Arthritis Rheum. 2009;60(7):1915–22. DOI:10.1002/art.24596. Scire C, Montecucco C., Codullo V et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology (Oxford). 2009;48(9):1092–7. DOI:10.1093/rheumatology/kep171. Epub 2009 Jun 26. Smolen JS, Han C, van der Heijde DM et al .Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset (ASPIRE) Study Group. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Ann Rheum Dis. 2009;68:823–7. Aletaha D, Alasti F, Smolen JS. Rituximab dissociates the tight link between diseases activity and joint damage in rheumatoid arthritis patients. Ann Rheum Dis. 2012;72(1):7–12. DOI:10.1136/annrheumdis-2012-201970. Epub 2012 Aug 21. Emery P, Genovese M, van Vollenhoven R et al. Less radiographic progression with adalimumab plus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol. 2009;36(7):1421–41. DOI:10.3899/jrheum.081018. Epub 2009 Apr 15. Cohen S, Dore R, Lane N et al.; Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58(5):1299–309. DOI:10.1002/art.23417. Smolen J, Avila J, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis. 2012;71(5):687–93. DOI:10.1136/annrheumdis-2011-200395. Epub 2011 Nov 25.; https://rsp.mediar-press.net/rsp/article/view/1335

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1335
https://doi.org/10.14412/1995-4484-2013-1540

المؤلفون: E Panasyuk Yu, V Amirdzhanova N, Anastasia Avdeyeva Sergeyevna, E Luchikhina L, E Aleksandrova N, A Novikov A, E Nasonov L, Е. Панасюк Ю., Е. Лучихина Л., Елена Александрова Николаевна, А. Новиков А., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 51, No 2 (2013); 104-110 ; Научно-практическая ревматология; Vol 51, No 2 (2013); 104-110 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-2

مصطلحات موضوعية: DAS28, SDAI, rheumatoid arthritis, tocilizumab, quality of life, remission, ревматоидный артрит, тоцилизумаб, качество жизни, ремиссия заболевания

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/773/466; Амирджанова В.Н. Популяционные показатели качества жизни. Науч-практич ревматол 2008;1:36-48. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер арх 2010;5:64-71. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8:538-42. Assier E., Boissier M., Dayer J. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010;77:532-6. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54. Romano M., Polentarutti N., Fruscella P. et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6;315—25. Lally F., Smith E., Filer A. et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthr Rheum 2005;52:3460-9. Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74. Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthr Res 2002;4(Suppl 3):81-90. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthr Res Ther 2007;9:203. Kudo O., Sabokbar A., Pocock A. et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7. Nakahara H., Song J., Sugimoto M. et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthr Rheum 2003;48:1521-9. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010;49:15-24. Bettelli E., Carrier Y., Gao W. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8. Naka T., Nishimoto N., Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthr Res 2002;4(Suppl 3):233-42. Heinrich P.C., Behrmann I., Haan S. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374(Pt 1):1-20. Rose-John S., Scheller J., Elson G., Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36. Jones S.A., Richards PJ., Scheller J., Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005;25:241-53. Houssiau F.A., Devogelaer J.P., van Damme J. et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthr Rheum 1988;31:784-8. Kotake S., Sato K., Kim K.J. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95. Sack U., Kinne R.W., Marx T. et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993;13:45-51. Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebocontrolled, randomised trial. Lancet 2008;371:987-97. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80. Emery P., Keystone E., Tony H. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. Burmester G., Feis E., Kellner H. et al. Effectiveness and safety of Ше interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9. Sibilia J., Graninger W., Ostor A. et al. Comparison of tocilizumab as monotherapy or with add-on DMARDS in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 2011;70(Suppl 3):466. Patel A., Moreland L. Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy. Drug Des Devel Ther 2010;4:263-78. Fransen J., Stucki G., van Reil P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum 2003;49:214-24. Felson D., Anderson J., Lange M. et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthr Rheum 1998;41:1564-70. Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57. Aletaha D., Nell V., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res Ther 2005;7:796-806. Choy E., Isenberg D.A., Garrood T. et al. Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin 6 receptor monoclonal antibody. Arthr Rheum 2002;46:3143-50. Nishimoto N., Yoshizaka K., Miaysaka N. et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthr Rheum 2004;50:1761-9. Kremer J., Blanco R., Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthr Rheum 2011;63:609-21. Leffers H., Ostergaard M., Glintborg B. Rheumatoid arthritis patients treated in routine care efficacy of abatacept and tocilizumab based on data from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70(Suppl 3):463. Yoshida K., Kishimoto M., Tokuda Y. Tocilizumab vs TNF inhibitors: difference in the quality of remission. Ann Rheum Dis 2011;70(Suppl 3):470. Yazici Y., Curtis J., Ince A. et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis 2012;71:198-205. Iking-Konert C., Aringer M., Wollenhaupt J. et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011;70:1986-90. Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96. Maini P., Taylor P., Szechinski J. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthr Rheum 2006;54:2817-29. Emery P., Keystone E., Tony H.-P. IL-6 Receptor inhibition with tocilizumab improves arthritis refractory to anti-TNF biologics: results treatment outcomes in patients with rheumatoid from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008;67:1516-23. Nishimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9. BykerkV., Ostor A., Alvaro-Gracia J. et al. Tocilizumab in patients with active rheumatoid arthritis and an inadequate response to DMARDs and/or the TNF inhibitor therapy: a large open-label study close to clinical precice. Ann Rheum Dis 2012;71:1950-4. Dougados M., Kissel K., Sheeran T. et al. Adding tocilizumab or switching to tociluzumab monotherapy in methotrexate inadequate responders: 24-week symtomatic and structural results od a 2-year randomized controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50. Weinblatt E., Kremer J.M., Cush J.J. et al. Tocilizumab monotherapy and tocilizumab plus disease-modifying antirheumatic drugs in a US rheumatoid arthritis population with inadequate response to anti-tumor necrosis factor agents. Arthr Rheum 2011;63(Suppl):162.; https://rsp.mediar-press.net/rsp/article/view/773

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/773
https://doi.org/10.14412/1995-4484-2013-635

المؤلفون: Rita Osipyants Aleksandrovna, D Karateev E, E Panasyuk Yu, G Lukina V, A Smirnov V, S Glukhova I, E Aleksandrova N, A Volkov V, Р. Осипянц А., Дмитрий Каратеев Евгеньевич, Е. Панасюк Ю., Г. Лукина В., А. Смирнов В., С. Глухова И., Елена Александрова Николаевна, А. Волков В.

المصدر: Rheumatology Science and Practice; Vol 51, No 3 (2013); 255-260 ; Научно-практическая ревматология; Vol 51, No 3 (2013); 255-260 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-3

مصطلحات موضوعية: foot arthrosonography, rheumatoid arthritis, synovitis, functional impairments, артросонография стоп, ревматоидный артрит, синовит, нарушения функционального статуса

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1313/972; Trieb K. Management of the foot in rheumatoid arthritis. Bone Joint Surg 2005;87-B:1171—7. Michelson J., Easley M., Wigley F.M., Hellmann D. Foot and ankle problems in rheumatoid arthritis. Foot Ankle Int 1994;15:608-13. Kuper H.H., van Leeuwen M.A., van Riel P.L. et al. Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability. Br J Rheumatol 1997;36:855-60. Rojas-Villarraga A., Bayaona J., Zuluaga N. et al. The impact of rheumatoid foot on disability in Colombian patients with rheumatoid arthritis. BMC Musculoskelet Disoder 2009;10:67. Abdo R.V., Iorio L.J. Rheumatoid arthritis of the foot and ankle. J Am Acad Orthop Surg 1994;12:326-32. Landewe R., van der Heijde D., van der Linden S. et al. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006;65:637-41. Klinkhoff A.V., Bellamy N., Bombardier C. et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988;15:492-4. Backhaus M., Kamradt T., Sandrock D. et al. Arthritis of the finger joints. A comprehensive Approach Comparing Conventional Radiography, Scintigraphy, Ultrasound, and Contrast-Enhanced Magnetic Resonance Imaging. Arthr Rheum 1999;42:1232-45. Prevoo M.L.L., van Hoff M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joints counts. Arthr Rheum 1995;38:44-52. Wakefield R., Balint P., Szkudlarek M. et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005;32:2485-7. Hammer H., Haavardsholm E., Boyesen P. et al. Bone erosions at the distal ulna detected by ultrasonography are associated with structural damage assessed by conventional radiography and MRI: a study of patients with recent onset rheumatoid arthritis. Rheumatology 2009;48:1530-2. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3. Funck-Brentano T., Etchepare F., Joulin S. et al. Benefits of ultrasonography in the management of early arthritis: a cross-sectional study of baseline data from the ESPOIR cohort. J Rheumatol 2009;48:1515-9. Wakefield R., Green M., Marzo-Ortega H. et al. Should oligoarthritis be reclassified? Ultrasound reveals a high prevalence of subclinical disease. Ann Rheum Dis 2004;63:382-5. Filer A., de Pablo P., Allen G. et al. Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. Ann Rheum Dis 2011;70:5007. Dougados M., Devauchelle-Pensec V., Ferlet J. et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis 2012; doi:10.1136/annrheumdis-2012-201469. Magnani M., Salizzoni E., Mule R. et al. Ultrasonography detection of early bone erosions in the metacarpophalangeal joints of patients with rheumatoid arthritis. Clin Exp Rheumatol 2004;22:743-8. Lopez-Ben R., Bernreuter W., Moreland L., Alarcon G. Ultrasound detection of bone erosions in rheumatoid arthritis: A comparison to routine radiographs of the hands and feet. Skeletal Radiol 2004;33:80-4. Ohrndorf S., Naumann L., Dietz E. et al. Evaluation of the 7-Joint Ultrasound Score (US7) by One Year Follow-up Data with Regard to Disease Duration. Arthr Rheum 2009;60(Suppl 10):1467. McNally E. Ultrasound of the small joints of the hand and feet: current status. Skeletal Radiol 2008;37:99-113. Grassi W., Filippucci E., Farina A. et al. Ultrasonography in the evaluation of bone erosions. Ann Rheum Dis 2001;60:98-103. Riente L., Delle Sedie A., Scire C. et al. Utrasound imaging for the rheumatologist. XXXI. Sonographic assessment of the foot in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011;29:1-5. Hameed B., Pilcher J., Heron C. et al. The relation between composite ultrasound measures and the DAS 28 score, its components and acute phase markers in adult RA. Rheumatology 2008;47:476-80. Naredo E., Bonilla G., Gamero F. et al. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005;64:375-81. Назаренко Г.И., Героева И.Б., Хитрова А.Н. и др. Возможности ультразвукового исследования в оценке активности воспалительного процесса и эффективности лечения пациентов с ревматоидным артритом. Ультразвук и функц диагн 2007;5:83-91. Scheel A., Hermann K.-G., Kahler E. et al. A novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthr Rheum 2005;52:733-43. Treslev L., Torp-Pedersen S., Savnik A. et al. Doppler ultrasound and magnetic resonance imaging of synovial inflammation of the hand in rheumatoid arthritis. Arthr Rheum 2003;48:2434-41. Александрова Е.Н., Насонов Е.Л. Инновационные технологии в лабораторной диагностике ревматических заболеваний. Науч-практич ревматол 2010;2:13-20. Van der Leeden M., Steultjens M., Dekker J. et al. The relationship of diseases duration to foot function, pain and disability in rheumatoid arthritis patients with foot complaints. Clin Exp Rheumatol 2007;25:275-80. Puolakka K., Kautiainen H., Pekurinen M. et al. Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis 2006;65:899-904. Вакуленко О.Ю., Кричевская О.А., Горячев Д.В. и др. Взаимосвязь клинических характеристик ревматоидного артрита с трудоспособностью и производительностью труда. Науч-практич ревматол 2012;52(3):60—67. Rojas-Villarraga A., Bayona J., Zuluaga N. et al. The impact of rheumatoid foot on disability in Colombian patients with rheumatoid arthritis. BMC Musculoskeletal Disorders 2009;10:67. Hooper L., Bowen C., Gates L. et al. Prognostic indicators of foot-related disability in patients with rheumatoid arthritis: results of a prospective three-year study. Arthr Care Res 2012;64:1116-24.; https://rsp.mediar-press.net/rsp/article/view/1313

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1313
https://doi.org/10.14412/1995-4484-2013-1497

المؤلفون: Irina Guseva Anatolyevna, E Panasyuk Yu, N Soroka E, A Avdeeva S, E Aleksandrova N, E Luchikhina L, E Gubar E, E Fedorenko V, T Gavva N, E Tsvetkova S, E Loginova Yu, E Samarkina Yu, G Lukina V, D Trofimov Yu, E Nasonov L, Е. Панасюк Ю., Елена Александрова Николаевна, Е. Лучихина Л., Г. Лукина В., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 51, No 4 (2013); 377-382 ; Научно-практическая ревматология; Vol 51, No 4 (2013); 377-382 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-4

مصطلحات موضوعية: rheumatoid arthritis, therapeutic efficiency, tocilizumab, polymorphism, genetic markers, ревматоидный артрит, эффективность терапии, тоцилизумаб, полиморфизм, генетические маркеры

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1148/820; Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Тер арх 2007;5:5-8. Насонов Е.Л. Инновационные технологии в лечении аутоиммунных ревматических заболеваний. Практ мед 2008;25:3-4. Сигидин Я.А., Лукина Г.В. Биологическая терапия в ревматологии. М.: Практическая медицина, 2009;302 с. Waldburger J.M., Firestein G.S. Garden of therapeutic delights: new targets in rheumatic diseases. Arthr Res Ther 2009;11:206. Orlewska E., Ancuta I., Anic B. et al. Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. Med Sci Monit 2011;17:SR1—13. Tak P.P., Kalden J.R. Advances in rheumatology: new targeted therapeutics. Arthr Res Ther 2011;13(Suppl 1):S5. Rubbert-Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthr Res Ther 2009;11(Suppl 1):S1. Насонов Е.Л. Новые возможности фармакотерапии ревматических болезней - ингибирование интерлейкина 6. Клин фармакол тер 2008;1:60-7. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер арх 2010;5:64-71. Kishimoto T. IL-6: from its discovery to clinical applications. Intern Immunol 2010;22:347-52. Rose-John S., Scheller J., Elson G. et al. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80;227—36. Dayer J.-M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010;49:15-24. Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты многоцентрового исследования). Науч-практич ревматол 2010;2:21-9. Панасюк Е.Ю., Амирджанова В.А., Александрова Е.Н. и др. Быстрый эффект тозилизумаба при ревматоидном артрите. Науч-практич ревматол 2011;4:11-5. Александрова Е.Н., Панасюк Е.Ю., Авдеева А.С. идр. Динамика лабораторных биомаркеров у больных ревматоидным артритом на фоне терапии тоцилизумабом. Науч-практич ревматол 2011;3:14-9. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80. Hushaaw L.L., Sawaqed R., Sweis G. et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clinical Risk Manag 2010;6:143-52. Patel A.M., Moreland L.W. Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy. Drug Design Devel Ther 2010;4:263-78. Woodrick R., Ruderman E.M. Anti-interleukin-6 therapy in rheumatoid arthritis. Bull NYL Hosp J Dis 2010;68:211-7. Arnett F.C., Edworthy S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31:315-24. Кофиади И.А., Ребриков Д.В. Методы детекции однонуклеотидных полиморфизмов: аллель-специфическая ПЦР и гибридизация с олигонуклеотидной пробой. Генетика 2006;42:22-32. Трофимов Д.Ю., Рагимов А.А., Абрамов Д.Д. и др. Популяционно-иммуногенетическая характеристика русской популяции в части генетических полиморфизмов, значимых для иммунного статуса человека. Физиол патол иммун сист 2009;2:3-7. Сергеев И.В., Хаитов М.Р, Трофимов Д.Ю. и др. Разработка методов для проведения широкомасштабных исследований полиморфизма генов, регулирующих различные компоненты иммунного ответа. Физиол и патол иммун системы 2009;4:6-10. Guseva I., Panasyuk E., Soroka N. et al. The influence of the genetic polymorphisms on the response to treatment of active rheumatoid arthritis with Tocilizumab. Ann Rheum Dis 2011;70(Suppl 3):465. Wang J., Bansal A., Martin M. et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J 2012;13:1-7. Emery P., Dörner T. Optimising treatment in rheumatoid arthritis: a rewiew of potential biological markers of response. Ann Rheum Dis 2011;70:2063-70. Bridges S.L. Jr. Personalized medicine in rheumatoid arthritis: hopes and challenges. Bull NYU Hosp Jt Dis 2007;65:174-7. Plenge R.M., Cotsapas C., Davies L. et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007;39:1477-82. Thomson W., Bartpm A., Ke X. et al. Rheumatoid arthritis association at 6q23. Nat Genet 2007;9:1431-3. Bowes J., Lawrence R., Eyre S. Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis. Hum Genet 2010;128:627-33. Dieguez-Gonzalez R., Calaza M., Perez-Pampin E. et al. Aalysis of TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility. Arthr Res Ther 2009;11:R42. Shimane K., Kochi Y., Horita T. et al. The association of a non-synonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthr Rheum 2010;62:574-9. Vereecke L., Beyaert R., van Loo G. Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease. Biochem Soc Trans 2011;39:1086-91. Li L., Hailey D.W., Soetandyo N. et al. Localization of A20 to a lysosome-associated compartment and its role in NF-kB signaling. Biochim Biophys Acta 2008;1783:1140-9. Vereecke L., Beyaert R., van Loo G. The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009;30:383-91. Van Loo G., Beyaert R. Negative regulation of NF-kB and its involvement in rheumatoid arthritis. Arthr Res Ther 2011;13:R221. Elsby L.M., Orozco G., Denton J. et al. Functional evaluation of TNFAIP3 (A20) in rheumatoid arthritis. Clin Exp Rheumatol 2010;28:708-14. Koczan D., Drynda S., Hecker M. et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthr Res Ther 2008;10:R50. Plant D., Farragher T., Flynn E. et al. A genetic marker at the OLIG3/TNFAIP3 locus associates with methotrexate continuation in early inflammatory polyarthritis: results from the Norfolk Arthritis Register. Pharmacogenomics J 2012;12:128-33.; https://rsp.mediar-press.net/rsp/article/view/1148

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1148
https://doi.org/10.14412/1995-4484-2013-1247

المؤلفون: Rita Osipyants Aleksandrovna, D Karateev E, E Panasyuk Yu, G Lukina V, E Aleksandrova N, S Glukhova I, A Volkov V, E Nasonov L, Р. Осипянц А., Дмитрий Каратеев Евгеньевич, Е. Панасюк Ю., Г. Лукина В., Елена Александрова Николаевна, С. Глухова И., А. Волков В., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 51, No 4 (2013); 383-386 ; Научно-практическая ревматология; Vol 51, No 4 (2013); 383-386 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-4

مصطلحات موضوعية: ultrasonography, ultrasound indices of the dominant hand, rheumatoid arthritis, tocilizumab, ультрасонография, ультразвуковые индексы доминирующей кисти, ревматоидный артрит, тоцилизумаб

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1149/821; Насонов Е.Л. Ревматоидный артрит как общемедицинская проблема. Терапевт архив 2004;5:5-7. Каратеев Д.Е., Олюнин Ю.А., Лучихина Е.Л. Новые классификационные критерии ревматоидного артрита ACR/EULAR 2010 г. — шаг вперед к ранней диагностике. В кн.: Насонов Е.Л. (ред.). Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. М.: ИМА-ПРЕСС, 2012;46—54. Насонов Е.Л. Ревматология: Национальное руководство. М.: ГЭОТАР-Медиа, 2010. Чичасова Н.В., Владимиров С.А., Имаметдинова Г.Р. и др. Функциональные исходы ревматоидного артрита при различных способах противовоспалительной терапии. Науч-практич ревматол 2010;2:30-36. Scott D.L. The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria. Arthr Rheum 2002;46:286-90. Насонов Е.Л. Почему необходима ранняя диагностика и лечение ревматоидного артрита? Рус мед журн 2002;10:1009-14. Emery P., Dougados M., Tak P. et al. Treat to Target — tailoring therapy in rheumatoid arthritis. European musculoskeletal review. Rheumatoid arthritis. Touch briefings 2011;1 —7. Meenagh G., Filippucci E., Delle Sedie A. et al. Ultrasound imaging for the rheumatologist XIX. Imaging modalities in rheumatoid arthritis. Clin Exp Rheumatol 2009;27:3-6. Kamishima T., Tanimura K., Shimizu M. et al. Monitoring antiinterleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger. Skeletal Radiol 2010;doi 10.1007/s00256-010-1064—4. Filippucci E., Iagnocco A., Salaffi F. et al. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis 2006;65:1433-7. Iagnocco A., Perella C., Naredo E. et al. Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography. Clin Rheumatol 2008;27:491-6. Prevoo M.L.L., van't Hoff M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joints counts. Arthr Rheum 1995;38:44-52. Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57. Wakefield R., Balint P., Szkudlarek M. et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005;32:2485-7. Kawashiri S.-Y., Kawakami A., Iwamoto N. et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. J Rheumatol 2010;doi:10.1093/rheumatology/keq415. Backhaus M., Ohrndorf S., Kellner H. et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthr Rheum 2009;61:1194-201. Naredo E., Rodriguez M., Campos C. et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power Doppler ultrasonographic assessment ofjoint inflammation in rheumatoid arthritis. Arthr Rheum 2008;59:515-22. Prevoo M.L., van't Hof M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995;38:44-8. Scire C.A., Montecucco C., Codullo V. et al. Ultrasonographic evaluation of joint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. Rheumatology 2009;48:1092-7. Hammer H., Kvien T. Comparisons of 7- to 78-joint ultrasonography scores: All different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis. Arthr Res Ther 2011;13:R78;doi:10.1186/ar3341. Schmidt W.A. Technology Insight: the role of color and power Doppler ultrasonography in rheumatology. Nat Clin Pract Rheum 2007;3:35-42.; https://rsp.mediar-press.net/rsp/article/view/1149

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1149
https://doi.org/10.14412/1995-4484-2013-1248

المؤلفون: Rita Osipyants Aleksandrovna, D Karateev E, E Panasyuk Yu, G Lukina V, A Smirnov V, S Glukhova I, E Aleksandrova N, A Volkov V, E Nasonov L, Р. Осипянц А., Дмитрий Каратеев Евгеньевич, Е. Панасюк Ю., Г. Лукина В., А. Смирнов В., С. Глухова И., Елена Александрова Николаевна, А. Волков В., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 51, No 2 (2013); 132-137 ; Научно-практическая ревматология; Vol 51, No 2 (2013); 132-137 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-2

مصطلحات موضوعية: sonographic destruction index, hand joint ultrasonography, rheumatoid arthritis, X-ray progression of structural changes, сонографический индекс деструкции, ультрасонография суставов кисти, ревматоидный артрит, рентгенологическое прогрессирование структурных изменений

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/777/470; Ревматология: Национальное руководство. Под ред. Е.Л. Насонова. M.: ГЭОTАР-Mедиа, 2010. Smolen J., Aletaha D., Bijsma J. et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:613-7. Каратеев Д.Е. Современный взгляд на проблему быстропрогрессирующего ревматоидного артрита. Совр ревматол 2010;2:37-42. Smolen J.S., van der Heijde D.M., St Clair E.W. et al. Predictors ofjoint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthr Rheum 2006;54:702-10. Александрова Е.Н., Чемерис Н.А., Каратеев Д.Е. и др. Антитела к циклическому цитруллинированному пептиду при ревматоидном артрите. Tер арх 2004;12:64-8. Emery P., McInnes I., van Vollenhoven R., Kraan М. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008;47:392-8. Van der Heijde D.M., van Riel P.L., van Leeuwen M.A. et al. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25. Quinn M.A., Conaghan P., O'Connor P. et al. Very early treatment with infliximab in addition to methotrexate in early, poor-progno-sis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal. Arthr Rheum 2005;52:27-35. Brown A.K., Conaghan P.G., Karim Z. et al. An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthr Rheum 2008;58:2958-67. Aletaha D., Alasti F., Smolen J. Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. Ann Rheum Dis 2011;70:1975-80. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-85. Klinkhoff A.V., Bellamy N., Bombardier C. et al. An experiment in reducing interobserver variability of the examination for joint tenderness. J Rheumatol 1988;15:492-4. Sharp J., Bluhm G., Brook A. et al. Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthr Rheum 1985;28:16-24. Backhaus M., Kamradt T., Sandrock D. et al. Arthritis of the finger joints. A comprehensive Approach Comparing Conventional Radiography, Scintigraphy, Ultrasound, and Contrast-Enhanced Magnetic Resonance Imaging. Arthr Rheum 1999;42:1232-45. Devauchelle-Pensec V., Saraux A., Berthelot J. et al. Ability of hand radiographs to predict a further diagnosis of rheumatoid arthritis in patients with early arthritis. J Rheumatol 2001;28:2603-7. Wakefield R., Gibbon W., Conaghan P. et al. The value of sonography in the detection of bone erosions in patients with rheumatoid arthritis: a comparison with conventional radiography. Arthr Rheum 2000;43:2762-70. Szkudlarek M., Narvestad E., Klarlund M. et al. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis. Comparison with magnetic resonance imaging, conventional radiography, and clinical examination. Arthr Rheum 2004;50:2103-12. Dоhn U., Ejbjerg B., Hasselquist M. et al. Detection of bone erosions in rheumatoid arthritis wrist joints with magnetic resonance imaging, computed tomography and radiography. Arthr Res Ther 2008;10:25. Hammer H., Haavardsholm E., Bоyesen P. et al. Bone erosions at the distal ulna detected by ultrasonography are associated with structural damage assessed by conventional radiography and MRI: a study of patients with recent onset rheumatoid arthritis. Rheumatology 2009;48:1530-2. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3. Smolen J., Aletaha D., Grisar J. et al. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now? Arthr Res Ther 2008;10:208. Сигидин Я.А., Лукина Г.В. Биологическая терапия в ревматологии. 2-е изд., доп.М.: Практическая медицина, 2009;302 с. Magnani M., Salizzoni E., Mule R. et al. Ultrasonography detection of early bone erosions in the metacarpophalangeal joints of patients with rheumatoid arthritis. Clin Exp Rheumatol 2004;22:743-8. Lopez-Ben R., Bernreuter W., Moreland L., Alarcon G. Ultrasound detection of bone erosions in rheumatoid arthritis: A comparison to routine radiographs of the hands and feet. Skeletal Radiol 2004;33:80-4. De Flaviis J., Scaglione P., Nessi R. et al. Ultrasonography of the hand in rheumatoid arthritis. Acta Radiol 1988;29:457-60. Bajaj S., Lopez-Ben R., Oster R., Alarcon G. Ultrasound detects rapid progression of erosive disease in early rheumatoid arthritis: A prospective longitudinal study. Skeletal Radiol 2007;36:123-8. Scheel A., Hermann K., Ohrndorf S. et al. Prospective 7-year follow-up imaging study comparing radiography, ultrasonography and magnetic resonance imaging in rheumatoid arthritis finger joints. Ann Rheum Dis 2006;66:595-600. Szkudlarek M., Klarlund M., Narvestad E. et al. Ultrasonography of the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis: A comparison with magnetic resonance imaging, conventional radiography and clinical examination. Arthr Res Ther 2006;52:8. Backhaus M., Ohrndorf S., Kellner H. et al. Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthr Rheum (Arthr Care Res) 2009;61:1194-201. Kawashiri S.-Y., Kawakami A., Iwamoto N. et al. The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis. J Rheumatol 2010; doi:10.1093/rheumatology/keq415. Prevoo M., van't Hof M., Kuper H. et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995;38:44-8. Scire C., Montecucco C., Codullo V. et al. Ultrasonographic evaluation ofjoint involvement in early rheumatoid arthritis in clinical remission: power Doppler signal predicts short-term relapse. J Rheumatol 2009;48:1092-7. Hammer H., Kvien T. Comparisons of 7to 78-joint ultrasonography scores: All different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis. Arthr Res Ther 2011;13:78. Chary-Valckenaere I., Sommier J., Michel-Batot C. et al. Erosion and joint space narrowing in RA: proposition for a new semiquantitave score (ScuSST: Scoring by UltraSound Structural Total) [abstract]. Arthr Rheum 2006;54(Suppl):139. Funck-Brentano T., Etchepare F., Joulin S. et al. Benefits of ultrasonography in the management of early arthritis: a cross-sectional study of baseline data from the ESPOIR cohort. J Rheumatol 2009;48:1515-9. Иевлева Л.В., Сатыбалдыев А.М. Особенности ревматоидного артрита, начавшегося у лиц в возрасте 50 лет и старше. В кн.: Ревматоидный артрит. Под ред. члена-корр. АМН СССР проф. В.А.Насоновой (СССР) и проф. В. Лайне (Финляндия). М.: Медицина, 1983.; https://rsp.mediar-press.net/rsp/article/view/777

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/777
https://doi.org/10.14412/1995-4484-2013-639

المؤلفون: Rita Osipyants Aleksandrovna, D Karateev E, E Panasyuk Yu, G Lukina V, A Smirnov V, S Glukhova I, E Aleksandrova N, A Volkov V, E Nasonov L, Р. Осипянц А., Д. Каратеев Е., Е. Панасюк Ю., Г. Лукина В., А. Смирнов В., С. Глухова И., Е. Александрова Н., А. Волков В., Е. Насонов Л.

المصدر: Rheumatology Science and Practice; Vol 51, No 1 (2013); 38-43 ; Научно-практическая ревматология; Vol 51, No 1 (2013); 38-43 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2013-1

مصطلحات موضوعية: hand ultrasonography, rheumatoid arthritis, structural progression, inflammatory activity, tocilizumab, ультрасонография кистей, ревматоидный артрит, структурное прогрессирование, воспалительная активность, тоцилизумаб

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1109/782; Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой М.: ГЭОТАР-Медиа, 2008;296. Hau M., Schultz H., Tony H.-P. et al. Evaluation of pannus and vascularization of the metacarpophalangeal and proximal inter-phalangeal joints in rheumatoid arthritis by high-resolution ultrasound (multidimensional linear array). Arthr Rheum 1999;42:2303-8. Pap T., Distler O. Linking angiogenesis to bone of destruction in arthritis. Arthr Rheum 2005;52:1346-8. Koch A.E. Review: angiogenesis: implications for rheumatoid arthritis. Arthr Rheum 1998;41:951-62. Naredo E., Bonilla G., Gamero F. et al. Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. Ann Rheum Dis 2005;64:375-81. Puolakka K., Kautiainen H., Mottonen T. et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of the work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthr Rheum 2004;50:55-62. Сигидин Я.А., Лукина Г.В. Биологическая терапия в ревматологии.2-е изд., доп. М.: Практическая медицина, 2009;302 с. Чичасова Н.В., Владимиров С.А., Имаметдинова Г.Р. и др. Функциональные исходы ревматоидного артрита при различных способах противовоспалительной терапии. Науч-практич ревматол 2010;2:30-6. Каратеев Д.Е., Олюнин Ю.А. О классификации ревматоидного артрита. Науч-практич ревматол 2008;1:5-16. Backhaus М., Kamradt T., Sandrock D. et al. Arthritis of the finger joints. A comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthr Rheum 1999;42:1232-45. Ejbjerg B.J., Vestergaard A., Jacobsen S. et al. The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score. Arthr Rheum 2005;52:2300-6. Szkudlarek M., Narvestad E., Klarlund M. et al. Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography and clinical examination. Arthr Rheum 2004;50:2103-12. Jimenez-Boj E., Nobauer-Huhmann I., Hanslik-Schnabel B. et al. Bone erosions and bone marrow edema as defined by magnetic resonance imaging reflect true bone marrow inflammation in rheumatoid arthritis. Arthr Rheum 2007;56:1118-24. Fukae J., Isobe M., Kitano A. et al. Radiographic prognosis of finger joint damage predicted by early alteration in synovial vascularity in patients with rheumatoid arthritis: potential utility of power Doppler sonography in clinical practice. Arthr Care Res 2011;63:1247-53. Conaghan P., Emery P., Ostergaard M. et al. Assessment by of inflammation and damage in rheumatoid arthritis patients with methotrexate inadequate response response receiving golimumab: results of the GO-FORWARD trial. Ann Rheum Dis 2011;70:1968-74. Cheung P.P., Dougados M., Gossec L. Reliability of ultrasonography to detect synovitis in rheumatoid arthritis: a systematic literature review of 35 studies (1, 415 patients). Arthr Care Res (Hoboken) 2010;62:323-34. Newman J.S., Laing T.J., McCarthy C.J. et al. Power Doppler sonography of synovitis: assessment of therapeutic response: preliminary observations. Radiology 1996;198:582-4. Hau M., Kneitz C., Tony H.P. et al. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). Ann Rheum Dis 2002;61:55-8. Naredo E., Rodrigez M., Campos C. et al. Validity, reproducibility, and responsiveness of a twelve-joint simplified power doppler ultrasonographic assessment of joint inflammation in rheumatoid arthritis. Arthr Rheum (Arthr Care Res) 2008;59:515-22. Filippucci E., Iagnocco A., Salaffi F. et al. Power Doppler sonography monitoring of synovial perfusion at the wrist joints in patients with rheumatoid arthritis treated with adalimumab. Ann Rheum Dis 2006;65:1433-7. Nishimoto N., Kishimoto T. Interleukin 6, from bench to bedside. Nat Clin Praс Rheumatol 2006;11:619-26. Насонов Е.Л. Применение тоцилизумаба (Актемры) при ревматоидном артрите. Науч-практич ревматол 2009;3(Прил.):18-27. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80. Панасюк Е.Ю., Амирджанова В.Н., Александрова Е.Н. и др. Быстрый эффект тоцилизумаба при ревматоидном артрите. Науч-практич ревматол 2011;4:11-6. Brown A.K., Quinn M.A., Karim Z. et al. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthr Rheum 2006;54:3761-73. Bresnihan B., Kane D. Sonography and subclinical synovitis. Ann Rheum Dis 2004;63:33-4. Prevoo M.L.L., van Hoff M.A., Kuper H.H. et al. Modified disease activity scores that include twenty-eight-joints counts. Arthr Rheum 1995;38:44-52. Van der Heijde D. How to read radiografhs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3. Wakefield R., Balint P., Szkudlarek M. et al. Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 2005;32:2485-7. Scheel A.K., Hermann K.-G.A., Kahler E. et al. A novel ultrasonographic synovitis scoring system suitable for analyzing finger joint inflammation in rheumatoid arthritis. Arthr Rheum 2005;52:733-43. Kamishima T., Tanimura K., Shimizu M. et al. Monitoring antiinterleukin 6 receptor antibody treatment for rheumatoid arthritis by quantitative magnetic resonance imaging of the hand and power Doppler ultrasonography of the finger. Skeletal Radiol 2011;40:745-55. Hama M., Uehara T., Takase K. et al. Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis patients receiving tocilizumab-preliminary data. Rheumatol Int 2012;32:1327-33. Naredo E., Moller I., Cruz A. et al. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Arthr Rheum 2008;58:2248-56. Naredo E., Collado P., Cruz A. et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: predictive value in disease activity and radiologic progression. Arthr Rheum (Arthr Care Res) 2007;57:116-24. Fukae J., Kon Y., Henmi M. et al. Change of synovial vascularity in a single finger joint assessed by power Doppler sonography correlated with radiografhic change in rheumatoid arthritis: comparative study of a novel quantitative score with a semiquantitative score. Arthr Care Res 2010;62:657-63. Dohn U., Ejbjerg B., Boonen A. et al. No overall progression and occasional repair of erosions despite persistent inflammation in adalimumab-treated rheumatoid arthritis patients: results from a longitudinal comparative MRI, ultrasonography, CT and radiography study. Ann Rheum Dis 2011;70:252-8. Taylor P.C., Steuer A., Gruber J. et al. Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthr Rheum 2004;50:1107-16. Kume K., Amano K., Yamada S. et al. Very early improvements at the wrist and hand assessed by power Doppler sonography predict later favorable responses in Tocilizumab-treated RA patients. Arthr Care Res 2011;63:1477-81. Smolen J., Aletaha D., Bijlsma J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. Каратеев Д.Е., Лучихина Е.Л. Современные принципы лечения ревматоидного артрита: акцент на раннюю агрессивную терапию. Эффект фармакотер 2011;1:12-7.; https://rsp.mediar-press.net/rsp/article/view/1109

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1109
https://doi.org/10.14412/1995-4484-2013-1199

المؤلفون: Anastasia Avdeyeva Sergeyevna, E Aleksandrova N, E Panasyuk Yu, A Novikov A, M Cherkasova V, E Nasonov L, Елена Александрова Николаевна, Е. Панасюк Ю., А. Новиков А., М. Черкасова В., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 50, No 3 (2012); 25-32 ; Научно-практическая ревматология; Vol 50, No 3 (2012); 25-32 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-3

مصطلحات موضوعية: DAS 28, CDAI, rheumatoid arthritis, tocilizumab, SDAI, erythrocyte sedimentation rate, C-reactive protein, IgM/IgA rheumatoid factors, anti-cyclic citrullinated peptide antibodies, anti-modified citrullinated vimentin antibodies, immunoglobulins G, ревматоидный артрит, тоцилизумаб, СОЭ, С-реактивный белок, IgM/IgA ревматоидные факторы, антитела к циклическому цитруллинированному пептиду, антитела к модифицированному цитруллинированному виментину, иммуноглобулины G

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/842/534; Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А.Насоновой. М.: ГЭОТАР-Медиа, 2008;290-331. Фоломеева О.М., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяции России и США. Науч-практич ревматол 2008;4:4-14. Ревматология: Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2010. Van Vollenhoven R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41. Насонов Е.Л. Фармакотерапия ревматоидного артрита -взгляд в 21 век. Клин мед 2005;6:8-12. Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008;181:151-60. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер арх 2010;5:64-71. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8:538-42. Assier E., Boissier M., Dayer J. Interleukin-6: from identification of the cytokine to development of targeted treatments. Joint Bone Spine 2010;77:532-6. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54. Romano M., Polentarutti N., Fruscella P. et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997;6:315-25. Lally F., Smith E., Filer A. et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthr Rheum 2005;52:3460-9. Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-74. Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthr Res 2002;4(Suppl. 3):81-90. Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthr Res Ther 2007;9:203. Kudo O., Sabokbar A., Pocock A. et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7. Nakahara H., Song J., Sugimoto M. et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthr Rheum 2003;48:1521-9. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010;49:15-24. Bettelli E., Carrier Y., Gao W. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-8. Naka T., Nishimoto N., Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthr Res 2002;4(Suppl. 3):233-42. Heinrich P.C., Behrmann I., Haan S. et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374(Pt 1):1-20. Rose-John S., Scheller J., Elson G., Jones S.A. Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 2006;80:227-36. Jones S.A., Richards PJ., Scheller J., Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res 2005;25:241-53. Houssiau F.A., Devogelaer J.P., van Damme J. et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthr Rheum 1988;31:784-8. Kotake S., Sato K., Kim K.J. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95. Sack U., Kinne R.W., Marx T. et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993;13:45-51. Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч-практич ревматол 2009;2:21-9. Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80. Emery P., Keystone E., Tony H.P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. Nishimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab mono-therapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9. Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96. Burmester G., Feist E., Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9. Oldfield V., Dhillon S., Plosker G.L. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-32. Frey N., Grange S., Woodworth T. Relationship between serum concentration of the interleukin-6 receptor inhibitor tocilizumab and C-reactive protein reduction in RA patients: 6 months data from a phase 3 study. Arthr Rheum 2007;56(Suppl. 9):148-9. Choy E.H., Isenberg D.A., Garrood T. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthr Rheum 2002;46:3143-50. Nishimoto N., Terao K., Mima T. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64. Garnero P., Thompson E., Woodworth T. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthr Rheum 2010;62:33-43. Yokoe I., Nishio S., Sato H., Kobayashi H. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Mod Rheumatol 2011;21:710-4. Roll P., Muhammad K., Schumann M. In vivo effect of the anti interleukin-6 receptor inhibitor tocilizumab on the B-cell compartment. Arthr Rheum 2011;63(5):1255-64. Александрова Е.Н., Панасюк Е.Ю., Авдеева А.С. и др. Динамика лабораторных биомаркеров у больных ревматоидным артритом на фоне терапии тоцилизумабом. Науч-практич ревматол 2011;3:14-9. Панасюк Е.Ю., Амирджанова В.Н., Александрова Е.Н. и др. Быстрый эффект тоцилизумаба при ревматоидном артрите. Науч-практич ревматол 2011;4:11-6. Fransen J., Stucki G., van Reil P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum 2003;49:214-24. Prevoo M., van’t Hof M., Kuper H. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthr Rheum 1995;38:44-8. Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57. Aletaha D., Nell V., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res Ther 2005;7(4):796-806. Rintelen B., Sautner J., Haindl P. et al. Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol 2009;38:336-41. Shaver T.S., Anderson J.D., Weidensaul D.N. et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35:1015-22. Kawashiri S., Kawakami A., Iwamoto N. et al. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Mod Rheumatol 2011;21:370-4. Smolen J., Alasti F., Aletaha D. Application of the clinical disease activity index (SDAI) which does not comprise an acute phase reactant (APR) reveals the efficacy of tocilizumab irrespective of the inclusion of an APR for assessment of response. Ann Rheum Dis 2009;68(Suppl. 3):355. Aletaha D., Alasti F., Smolen J. Defining remission in patients receiving tocilizumab is influenced by the choice of the composite index rather than by specific effects on the acute phase response. Ann Rheum Dis 2009;68(Suppl. 3):123. Nakazaki S., Murayama T., Kato S. The validity of 28-joint disease activity scoring using ESR in rheumatoid arthritis with tocilizumab. Ann Rheum Dis 2011;70(Suppl. 3):618. Funahashi K., Koyano S., Miura T. et al. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. Mod Rheumatol 2009;19:507-12. Koyama Y., TadaT., Ohta T., Fujii K. Reevaluation of quantitative assessment methods of rheumatoid arthritis should be considered for the treatment with anti-IL-6 receptor antibody. Ann Rheum Dis 2009;68(Suppl. 3):582. Jones G., Gu J.R., Lowenstein M. et al. Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: the ambition study. Ann Rheum Dis 2008;67(Suppl. II):89. Levi M., Frey N., Grange S. et al. Reduction in inflammatory biomarkers with increasing exposure to the IL-6 inhibitor, tocilizumab, in patients with rheumatoid arthritis: graphical analysis of pooled data. Ann Rheum Dis 2008;67(Suppl. II):192. Beaulieu A., McKay J., Pavelka K. et al. Treatment with the humanized anti-interleukin-6 receptor antibody tocilizumab results in rapid improvements in the signs and symptoms of rheumatoid arthritis: results from a pooled analysis of clinical trial data from option and toward. Ann Rheum Dis 2008;67(Suppl. II):195. Nishimoto N., Yoshizaki K., Miyasaka N. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody. Arthr Rheum 2004;50:1761-9. Новиков А.А., Александрова Е.Н., Каратеев Д.Е. и др. Диагностическое значение антител к модифицированному циклическому виментину при раннем ревматоидном артрите. Клин лаб диагн 2008;8:27-9. Новиков А.А., Александрова Е.Н., Черкасова М.В. и др. Современные методы лабораторной диагностики ревматоидного артрита. Науч-практич ревматол 2010;1:31-45. Bang H., Lu thke K., Gauliard A. et al. Mutated citrullinated vimentin as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Ann Rheum Dis 2006;65(Suppl. II):144. Roland P., Mignot S., Bruns A. Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthr Res Ther 2008;10:142. Dejaco C., Duftner C., Klotz W. et al. Antibodies against mutated citrullinated vimentin fail to predict anti-TNFa treatment response in rheumatoid arthritis. Scand J Rheumatol 2009;38:66-76.; https://rsp.mediar-press.net/rsp/article/view/842

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/842
https://doi.org/10.14412/1995-4484-2012-705

المؤلفون: Anastasia Avdeyeva Sergeyevna, E Aleksandrova N, E Panasyuk Yu, G Lukina V, E Nasonov L, Елена Александрова Николаевна, Е. Панасюк Ю., Г. Лукина В., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 50, No 4 (2012); 49-56 ; Научно-практическая ревматология; Vol 50, No 4 (2012); 49-56 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-4

مصطلحات موضوعية: DAS 28, SDAI, CDAI, rheumatoid arthritis, tocilizumab, rituximab, remission, ревматоидный артрит, тоцилизумаб, ритуксимаб, ремиссия заболевания

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1032/705; Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А.Насоновой. М.: ГЭОТАР-Медиа, 2008; 290-331. Samuels J., Ng Y.S., Coupillaud C. et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005;201:1659-67. Насонов Е.Л. Применение ритуксимаба при ревматоидном артрите. Науч-практич ревматол 2009;1(Прил.):3-22. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008;118:3537-45. Smolen J.S., Aletaha D., Bijsma J.WJ. et al. For the T2T Exspert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч-практич ревматол 2009;2:21-9. Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер aрх 2010;5:64-71. Александрова Е.Н., Панасюк Е.Ю., Авдеева А.С. и др. Динамика лабораторных биомаркеров у больных ревматоидным артритом на фоне терапии тоцилизумабом. Науч-практич ревматол 2011;3:14-9. Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. Панасюк Е.Ю., Амирджанова В.Н., Александрова Е.Н. и др. Быстрый эффект тоцилизумаба при ревматоидном артрите. Науч-практич ревматол 2011;4:11 -6. Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96. Burmester G., Feist E., Kellner H. et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis 2011;70:755-9. Emery P., Fleishmann R., Filipowicz-Sosnowska A. et al. for the DANCER Study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled dose-range trial. Arthr Rheum 2006;54:1390-400 Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr Rheum 2006;54:2793-806. Emery P., Deodhar A., Rigby W.F. et al. Efficacy and safety of different doses and retreatment of Rituximab: a randomized, placebo-controlled trial in patients who are biologically naive with active rheumatoid arthritis and anadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX inadequate responders (SERENA)). Ann Rheum Dis 2010;69:1629-35 Rubbert-Roth A., Tak P.P., Zebrini C. et al. Efficacy and safety of various repeat treatment dosing regimes in Rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR) dosing regimens of rituximab in patients with active RA: results of a phase III randomized study (MIRROR). Rheumatology 2010;49:1683-93. McGonagle D., Tan A., Madden J. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. Rheumatology 2008;47:865-7. Assous N., Gossec L., Dieude P. Rituximab therapy in rheumatoid arthritis in daily practice. Rheumatology 2008;35:2. Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42:244-57. Aletaha D., Nell V., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res Ther 2005;7:796-806. Rintelen B., Sautner J., Haindl P. et al. Comparison of three rheumatoid arthritis disease activity scores in clinical routine. Scand J Rheumatol 2009;38:336-41. Shaver T.S., Anderson J.D., Weidensaul D.N. et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008;35:1015-22. Fransen J., Stucki G., van Reil P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum 2003;49:214-24. Fransen J., Creemers C., van Reil P.L.C.M. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS 28) with the ARA preliminary remission criteria. Rheumatology 2004;43:1252-5. Felson D., Smolen J., Wells G. American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Arthr Rheum 2011;63:573-86. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80. Kremer J., Fleischmann R., Brzezicki J. et al. Tocilzumab inhibits structural joint damage, improved physical function, and increase DAS 28 remission rates in RA patients who respond inadequately to methotrexate: the LITHE study. Ann Rheum Dis 2009;68(Suppl.3):122 (OP-0157). Leffers H., Ostergaard M., Glintborg B. Rheumatoid arthritis patients treated in routine care - efficacy of abatacept and tocilizumab based on data from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70 (Suppl.3):463. Yoshida K., Kishimoto M., Tokuda Y. Tocilizumab vs TNF inhibitors: difference in the quality of remission. Ann Rheum Dis 2011;70(Suppl.3):470. Tak P., Rigby W., Rubbert-Roth A. et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011;70:39-46. Sellam J., Abbedd K., Rouanet S. et al. Pre-therapeutic descrease frequency of memory B cell is predictive of response to a first course of Rituximab in rheumatoid arthritis patients with inade-quate respose or intolerance to anti-TNF: data from the SMART trial. Ann Rheum Dis 2010;69(Suppl.3):490 [SAT0014]. Maini P., Taylor P., Szechinski J. et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in european patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthr Rheum 2006;54:2817-29. Emery P., Keystone E., Tony H.-P. IL-6 receptor inhibition with tocilizumab improves arthritis refractory to anti-TNF biologics: results treatment outcomes in patients with rheumatoid from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008;67:1516-23. Sibilia J., Graninger W., Ostor A. et al. Comparison of tocilizumab as monotherapy or with add-on DMARDS in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 2011;70 (Suppl.3):466. Nakazaki S., Murayama T., Kato S. The validity of 28-joint disease activity scoring using ESR in rheumatoid arthritis with tocilizumab. Ann Rheum Dis 2011;70(Suppl.3):618. Smolen J., Kavanaugh A., Tony H.P. et al. Rituximab significantly improves the clinical and simplified disease activity index (CDAI, SDAI) scores in patients with rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors (REFLEX). Ann Rheum Dis 2007;66(Suppl.II):439. Smolen J., Aletaha D. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis. Arthr Rheum 2011;63:43-52. Iking-Konert C., Aringer M., Wollenhaupt J. et al. Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria. Ann Rheum Dis 2011;70:1986-90.; https://rsp.mediar-press.net/rsp/article/view/1032

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1032
https://doi.org/10.14412/1995-4484-2012-1112

المؤلفون: Anastasia Avdeeva Sergeevna, A Smirnov V, E Panasyuk Yu, E Alexandrova N, E Nasonov L, А. Смирнов В., Е. Панасюк Ю., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 50, No 5 (2012); 25-29 ; Научно-практическая ревматология; Vol 50, No 5 (2012); 25-29 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-5

مصطلحات موضوعية: SDAI, CDAI, rheumatoid arthritis, tocilizumab, radiographic progression, ревматоидный артрит, тоцилизумаб, рентгенологическое прогрессирование

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1090/763; Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 290—331. Новиков А.А., Александрова Е.Н., Диатроптова М.А., Насонов Е.Л. Роль цитокинов в патогенезе ревматоидного артрита. Науч.-практич. ревматол. 2010; 2: 71—82. Jones G., Darian-Smith E., Kwok M. et al. Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate? Biologics 2012; 6: 155—61. Smolen J.S., Aletaha D., Bijsma J.W.J. et al. For the T2T Exspert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010; 69: 6317. Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008; (181): 151—60. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер. арх. 2010; 5: 64—71. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010; 49: 15—24. Fonseca J.E., Santos M.J., Canhao H. et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538—42. Kudo O., Sabokbar A., Pocock A. et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32: 1-7. Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthr Res 2002; 4(Suppl. 3): 81—90. Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74. Kotake S., Sato K., Kim K.J. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95. Sack U., Kinne R.W., Marx T. et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993; 13: 45-51. Aletaha D., Nell V., Stamm T. et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthr Res Ther 2005: 7; R796—R806. Welsing P., Landewe R, van Riel P. et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthr Rheum 2004; 50: 2082—93. Frey N., Grange S., Woodworth T. Relationship between serum concentration of the interleukin-6 receptor inhibitor tocilizumab and C-reactive protein reduction in RA patients: 6 months data from a phase 3 study. Arthr Rheum 2007; 56(Suppl. 9): 148—9. Choy E.H., Isenberg D.A., Garrood T. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthr Rheum 2002; 46: 3143-50. Nishimoto N., Terao K., Mima T. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64. Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч.-практич. ревматол. 2009; 2: 21-9. Александрова Е.Н., Панасюк Е.Ю., Авдеева А.С. и др. Динамика лаб. ораторных биомаркеров у больных ревматоидным артритом на фоне терапии тоцилизумабом. Науч.-практич. ревматол. 2011; 3: 14-9. Панасюк Е.Ю., Амирджанова В.Н., Александрова Е.Н. и др. Быстрый эффект тоцилизумаба при ревматоидном артрите. Науч.-практич. ревматол. 2011; 4: 11-6. Garnero P., Thompson E., Woodworth T. Rapid and sustained improvement in bone and cartilage turnover markers with the antiinterleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate. Arthr Rheum 2010; 62: 33-43. Yokoe I., Nishio S., Sato H. et al. Comparison of MMP-3 levels in rheumatoid arthritis after treatment with tocilizumab or infliximab for 12 weeks. Mod Rheumatol 2011: 21: 710—4 Tanaka Y., Takeuchi T., Amano K. et al. Impact of tocilizumab therapy for remission quartet in rheumatoid arthritis-the result of 104 weeks follow up data of REACTION study. Arthr Rheum 2011; 63(Suppl.): S483. Tanaka Y., Takeuchi T., Amano K. et al. Impact of tocilizumab therapy after switching from tumor necrosis factor (TNF) inhibitors — prevention of joint damage by tocilizumab in patients with inadequate response to anti-TNF therapies. Arthr Rheum 2011; 63(Suppl.): S484. Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic beneët from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66: 1162—7. Kremer J., Blanco R., Brzosko M. et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthr Rheum 2011; 63: 609-21. Fleischmann R., Burgos-Vargas R., Skopouli F.N. et al. Tocilizumab inhibits radiographic progression, improves physical function, and gains efficacy over time: LITHE 2 year. Ann Rheum Dis 2010; 69(Suppl. 3): 384. Fransen J., Stucki G., van Reil P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum 2003; 49: 214-24. Smolen J., Breedveld F., Schiff M. et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003; 42: 244-57. Shaver T.S., Anderson J.D., Weidensaul D.N. et al. The problem of rheumatoid arthritis disease activity and remission in clinical practice. J Rheumatol 2008; 35: 1015-22. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999; 26: 743-5. Смирнов А.В. Атлас рентгенологической диагностики ревматоидного артрита. М.: ИМА-ПРЕСС, 2009. Takeuchi T., Tanaka Y., Amano K. et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients — REACTION 52-week study. Rheumatology 2011; 50: 1908-15. Svensson B., Boonen A., Albertsson K. et al. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. Arthr Rheum 2005; 52: 3360-70. Wassenberg S., Rau R., Steinfeld P. et al. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years a multicenter, double-blind, placebo-controlled trial. Arthr Rheum 2005; 52: 3371-80. Hafström I., Albertsson K., Boonen A. et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to diseasemodifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. Ann Rheum Dis 2009; 68: 508-13. Plant M.J., Williams A.L., O'Sullivan M.M. et al. Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthr Rheum 2000; 43: 1473-7. Van Leeuwen M.A., van Rijswijk M.H., van der Heijde D.M. et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. Br J Rheumatol 1993; 32: 9-13. Van der Heide A., Remme C.A., Hofman D.M. et al. Prediction of progression of radiologic damage in newly diagnosed rheumatoid arthritis. Arthr Rheum 1995; 38: 1466-74. Smolen J., Avila J., Aletaha D. et al. Tocilizumab (TCZ) inhibits progression of joint damage in rheumatoid arthritis (RA) irrespective of its antiinflammatory effects: disassociation of the link between inflammation and destruction. Arthr Rheum 2011; 63(Suppl.): S630. Dougados M., Kissel K., Amital H. et al. Double-blind study of tocilizumab plus methotrexate vs tocilizumab plus placebo in patients with active rheumatoid arthritis despite prior methotrexate: progression of structural damage, quality of life, and physical function at 24 weeks. Arthr Rheum 2011; 63(Suppl.): S1032.; https://rsp.mediar-press.net/rsp/article/view/1090

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1090
https://doi.org/10.14412/1995-4484-2012-1176

المؤلفون: Anna Starkova Sergeyevna, V Amirdzhanova N, A Avdeyeva S, E Panasyuk Yu, E Nasonov L, Е. Панасюк Ю., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 50, No 3 (2012); 33-37 ; Научно-практическая ревматология; Vol 50, No 3 (2012); 33-37 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-3

مصطلحات موضوعية: rheumatoid arthritis, tocilizumab, fatigue, visual analog scale, ревматоидный артрит, тоцилизумаб, усталость, визуальная аналоговая шкала

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/843/535; Tehlirian C.V., Bathon J.M. Rheumatoid arthritis: Clinical and laboratory manifestations. In: Klippel J.H., Stone J.H., Crofford L.J., White P.H. (eds). Primer on the Rheumatic diseases. 13th ed. NY: Springer, 2008;114-21. Pollard L.C., Choy E.H., Khoshaba B., Scott L. Fatigue in rheumatoid arthritis reflects pain not diseases activity. Rheumatology 2006;45:885-9. Kirwan J.R., Minnock P., Adebajo A. et al. Patient perspective: Fatigue as a recommended patient center outcome measure in rheumatoid arthritis. J Rheumatol 2007;34:1174-7. Belza B.L. Comparison of self reported fatigue in rheumatoid arthritis and controls. J Rheumatol 1995;2:639-43. Davis M.C., Zautra A.J., Younger J. et al. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immunol 2008;22:24-32. Wolfe F., Michaud K., Pincus T. Fatigue, rheumatoid arthritis and anti tumor necrosis factor theraphy: an investigation in 24.831 patients. J Rheunatol 2004;31:2115-20. Mathew A.J., Antony J., Eremenco S. et al. Health related quality of life in rheumatoid arthritis patients in South India. Singapore Med J 2007;50:800-3. Raj D.S.C. Role of Interleukin 6 in the anemia of chronic disease. Sem Arthr Rheum 2009;38(5):382-8. Галушко Е.А. Анемия хронического заболевания. Науч-практич ревматол 2009;3(Прил. 3):70-7. Han E., Rahman M.U., Doyle M.K. et al. Association of anemia and physical disability among patients with rheumatoid arthritis. J Rheumatol 2007;34:2177-82. Escobar M.E., Gerhardt C., Roesler E. et al. Anemia versus disease activity as cause of fatigue in rheumatoid arthritis. Acta Rumatol Port 2010;35:2-8. Smolen J.S., Breedveld Е.С., Eberal G. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthr Rheum 1995;38(1):38-43. Pincus T., Bergman M.J., Yazici Y. RAPID3 - An index of physical function, pain, and global status as «vital signs» to improve care for people with chronic rheumatic diseases. Bull of the NYU Hosp Joint Dis 2009;67(2):211-25. Aletaha D., Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): A review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheum 2005;23(Suppl. 39):100-8. Международные индексы оценки активности, функционального статуса и качества жизни больных ревматическими заболеваниями. М., 2007;13-6. Hyuser B.A., Parker J.C., Thoreson R. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthr Rheum 1998;41:2230-7. Yoshida K., Tokuda Y., Oshikawa H et al. An observational study of tocilizumab and TNF-a inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology 2011;50:20932099 doi:10.1093/rheumatology/ker295 Takeuchi T., Tanaka Y., Amano K. et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients - REACTION 52-week study. Rheumatology 2011;50(10):1908-15. Smolen J.S., Beaulieu A., Rubbert-Rot A. et al. Effect of interleukin-6 receptor inhibition with Tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled trial. Lancet 2008;371:987-97. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleikin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. Arthr Rheum 2008;58:2968-80. Emery P., Keystone E., Tony H.P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biological: results from a 24-week multicentre randomized placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. Nishimoto N., Hashimoto J., Miyasaka N. et al. Study of active controlled monotherapy used used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2006;65:59. Nashimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in desease activity and serum vascular endothelial growth factor by Il-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9. Jones G., Sebba A., Gu J. et al. Comparison of Tocilizumab monotherapy versus metotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69(1):88-96. Yusuf Y., Curtis J.R., Ince A. et al. Efficacy and safety of tocilizumab in patients with moderate to severe active ra and a previous inadequate response to DMARDs: The ROSE Study. Arthr Rheum 2010;62(Suppl.):S754 [1808].; https://rsp.mediar-press.net/rsp/article/view/843

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/843
https://doi.org/10.14412/1995-4484-2012-706

المؤلفون: Dmitry Karateev Evgenyevich, E Nasonov L, L Denisov N, M Stanislav L, E Panasyuk Yu, I Andrianova A, V Mazurov I, E Zhugrova S, Yu Uspensky P, L Belousova N, E Ilivanova P, G Matsiyevskaya K, G Aurtyunov P, K Lytkina A, R Saikovsky S, V Ardashev N, E Zhilyaev V, N Korshunov I, Дмитрий Каратеев Евгеньевич, Евгений Насонов Львович, Е. Панасюк Ю., В. Мазуров И., К. Лыткина А., Е. Жиляев В., Н. Коршунов И.

المصدر: Rheumatology Science and Practice; Vol 50, No 2 (2012); 14-19 ; Научно-практическая ревматология; Vol 50, No 2 (2012); 14-19 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2012-2

مصطلحات موضوعية: RAPID 1, RAPID 2, certolizumab pegol, rheumatoid arthritis, randomized clinical trial, цертолизумаба пэгол, ревматоидный артрит, рандомизированное клиническое исследование

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1161/833; Ревматология. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: ГЭОТАР-Медиа, 2006. Ревматология: Национальное руководство. Под ред. Е.Л. Насонова М.: ГЭОТАР-Медиа, 2008;720 с. Насонов Е.Л. Ревматоидный артрит как общемедицинская проблема. Тер арх 2004;5:5-7. Smolen J., Aletaha D., Bijlsma J. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7. Каратеев Д.Е. Академия ревматологии на российской земле. Consilium medicum 2010; экстравыпуск: 3-14. Каратеев Д.Е., Лучихина Е.Л. Современное состояние проблемы раннего артрита. Науч-практич ревматол 2010;4(прил. 2):27—31. Smolen J.S., Aletaha D., Machold K.P. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:163-77. Каратеев Д.Е. Низкая активность и ремиссия при ревматоидном артрите: клинические, иммунологические и морфологические аспекты. Науч-практич ревматол 2009;5:4-12. Насонов Е.Л. Фактор некроза опухоли-α - новая мишень для противовоспалительной терапии ревматоидного артрита. Клин фармакол тер 2001;1:64-70. Насонов Е.Л. Эффективность и безопасность ингибиторов фактора некроза опухоли-α при ревматоидном артрите. Рус мед журн 2008;16(24):1602—9. http://ru.wikipedia.org/wiki/ http://www.prodobavki.com/dobavki/E1521.html http://www.farcom-nn.ru/polietilenglicol Каратеев Д.Е. Вопросы иммуногенности биологических препаратов: теория и практика. Совр ревматол 2009;1:67-72. Keystone E., van der Heijde D., Mason D. Jr. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthr Rheum 2008;58:3319-29. Smolen J., Brzezicki J., Mason D., Kavanaugh A. Ann Rheum Dis 2007;66(Suppl. II):187 and Poster THU0202. Mease D., Mason D., Kavanaugh A. Poster presentation (Abstract 941), ACR Congress, 2007. Fleischmann R., Mason D., Cohen S. Ann Rheum Dis 2007;66:(Suppl. II):169. Keystone E.C., van der Heijde D., Mason D. et al. Ann Rheum Dis 2008;67(Suppl. II):186 and Poster THU0157. Smolen J., Landewe R.B., Mease P. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804. Strand V., Smolen J., van Vollenhoven R.F. et al. Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. Ann Rheum Dis 2011;70:996-1002.; https://rsp.mediar-press.net/rsp/article/view/1161

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1161
https://doi.org/10.14412/1995-4484-2012-1267

المؤلفون: E Aleksandrova N, E Panasyuk Yu, A Avdeyeva S, A Novikov A, G Lukina V, M Cherkasova V, N Klimova V, E Nasonov L, Елена Александрова Николаевна, Е. Панасюк Ю., А. Новиков А., Г. Лукина В., М. Черкасова В., Евгений Насонов Львович

المصدر: Rheumatology Science and Practice; Vol 49, No 3 (2011); 14-19 ; Научно-практическая ревматология; Vol 49, No 3 (2011); 14-19 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2011-3

مصطلحات موضوعية: rheumatoid arthritis, interleukin-6, interleukin-6 receptors, tocilizumab, erythrocyte sedimentation rate, C-reactive protein, IgM/IgA rheumatoid factor, anti-cyclic citrullinated peptide antibodies, anti-modified citrullinated vimentin antibodies, ревматоидный артрит, интерлейкин 6, рецепторы интерлейкина 6, тоцилизумаб, СОЭ, С-реактивный белок, IgM/IgA ревматоидные факторы, антитела к циклическому цитруллинированному пептиду, антитела к модифицированному цитруллинированному виментину

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/705/398; Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревмато- логия. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; 290-331 Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008; 118: 3537-45. Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010; 49: 15-24. Fonseca J.E., Santos M.J., Canlmo H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009; 8: 538-42. Romano M., Polentarutti N., Fruscella P et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 1997; 6: 315-25. Lally F., Smith E., Filer A. et al. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthr Rheum 2005; 52: 3460-9. Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74 Schett G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthr Res Ther 2007; 9: 203. Kudo O., Sabokbar A., Pocock A. et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32: 1-7. Paleolog E.M. Angiogenesis in rheumatoid arthritis. Arthr Res 2002; 4(Suppl. 3): 81-90 Bettelli E., Carrier Y., Gao W. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448-54. Andrews N.C. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004; 113: 1251-3. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 1351-62. Madhok R., Crilly A., Watson J., Capell H.A. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993; 52: 232-4. Robak T., Gladalska A., Stepien H., Robak E. Serum levels of interleukin-6 type cytokines and soluble-6 receptor in patients with rheumatoid arthritis. Med Inflam 1998; 7: 347-53. Chung S.-J., Kwon Y.-J., Park M.-C. et al. The correlation between increased serum concentrations of interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients. Yonsei Med J 2011; 52: 113-20. Okamoto H., Yamamura M., Morita Y. et al. The synovial expression and serum levels of interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M in rheumatoid arthritis. Arthr Rheum 1997; 40: 1096-105. Houssiau F.A., Devogelaer J.P., van Damme J. et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthr Rheum 1988; 31: 784-8. Kotake S., Sato K., Kim K.J. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95. Nishimoto N., Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008; 181: 151-60. Oldfield V., Dhillon S., Plosker G.L. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009; 69: 609-32. Насонов Е.Л. Новые подходы к фармакотерапии ревматоидного артрита: перспективы применения тоцилизумаба (моноклональные антитела к рецептору интерлейкина-6). Тер. арх. 2010; 5: 64-71. Frey N., Grange S., Woodworth T. Relationship between serum concentration of the interleukin-6 receptor inhibitor tocilizumab and C-reactive protein reduction in RA patients: 6 months data from a phase 3 study. Arthr Rheum 2007; 56(Suppl. 9): 148-9. Choy E.H., Isenberg D.A., Garrood T. et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthr Rheum 2002; 46: 3143-50. Nishimoto N., Terao K., Mima T. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64. Garnero P., Mareau E., Thompson T. et al. The antiinterleukin-6 receptor inhibitor tocilizumab combined with methotrexate has beneficial effects on bone and cartilage metabolism in patients with rheumatoid arthritis: results of a phase III 24-week randomized placebo-controlled study. Ann Rheum Dis 2008; 67(Suppl. II): 178. Насонов Е.Л., Панасюк Е.Ю., Булдаков С.Г. и др. Эффективность и безопасность тоцилизумаба при ревматоидном артрите (промежуточные результаты российского многоцентрового исследования). Науч.-практич. ревматол. 2009; 2: 21-9. Myers G.L., Rifai N., Tracy R.P. et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation 2004; 110: 545-9. Jones G., Gu J.R., Lowenstein M. et al. Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: the ambition study. Ann Rheum Dis 2008; 67(Suppl. II): 89. Levi M., Frey N., Grange S. et al. Reduction in inflammatory biomarkers with increasing exposure to the IL-6 inhibitor, tocilizumab, in patients with rheumatoid arthritis: graphical analysis of pooled data. Ann Rheum Dis 2008; 67(Suppl. II): 192. Beaulieu A., McKay J., Pavelka K. et al. Treatment with the humanized anti-interleukin-6 receptor antibody tocilizumab results in rapid improvements in the signs and symptoms of rheumatoid arthritis: results from a pooled analysis of clinical trial data from option and toward. Ann Rheum Dis 2008; 67(Suppl. II): 195 Smolen J.S., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008; 58: 2968-80 Emery P., Keystone E., Tony H.P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67: 1516-23. Nishimoto N., Miyasaka N., Yamamoto K. et al. Relationship between serum IL-6 levels after tocilizumab treatment an clinical remission in active rheumaroid arthritis patients. Ann Rheum Dis 2008; 67(Suppl. II): 90.; https://rsp.mediar-press.net/rsp/article/view/705

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/705
https://doi.org/10.14412/1995-4484-2011-567

المؤلفون: E Nasonov L, Elena Panasyuk Yuryevna, S Buldakov G, A Pavlova B, L Knyazeva A, R Kamalova G, I Vinogradova B, E Shikina A, T Raskina A, A Dmitriyeva A, R Saikovsky S, A Elonakov V, V Amirdzhanova N, E Aleksandrova N, Евгений Насонов Львович, Е. Панасюк Ю., С. Булдаков Г., Л. Князева А., И. Виноградова Б., Татьяна Раскина Алексеевна, А. Елонаков В., Елена Александрова Николаевна

المصدر: Rheumatology Science and Practice; Vol 48, No 2 (2010); 21-29 ; Научно-практическая ревматология; Vol 48, No 2 (2010); 21-29 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2010-2

مصطلحات موضوعية: tocilizumab, rheumatoid arthritis, functional activity, quality of life, тоцилизумаб, ревматоидный артрит, функциональная активность, качество жизни

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/1251/922; Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008;290-331. Фоломеева О.М., Галушко Е.А., Эрдес Ш.Ф. Распространенность ревматических заболеваний в популяции населения России и США. Науч.-практич ревматол 2008;4:4-14. Насонов Е.Л. Фармакотерапия ревматоидного артрита - взгляд в 21 век. Клин мед 2005;6:8-12. Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-71. Van Vollenhoven R.F. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41. Furst D.E., Keystone E.C., Kirkham B. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67:iii2-iii25. Du Pan S.M., Dehler S., Ciurea A. et al. Comparison of drug retention rates and causes of drug discontinuation between antitumor necrosis factor agents in rheumatoid arthritis. Arthr Care Res 2009;61:560-8. Nishimoto N., Kishimoto T. Interleukin 6, from bench to bedside. Nat Clin Praс Rheumatol 2006;11:619-26. Насонов Е.Л. Новые возможности фармакотерапии ревматических болезней - ингибирование интерлейкина 6. Клин фармакол тер 2008;1:60-7. Dayer J.-M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 2009;1-9, October 2003, on line. Rose-John S., Scheller J., Elson G. et al. Interleukin-6 is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukocyte Biol 2006;80:227. Foseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmune Rev 2009. doi:10.1016/j.autrev.2009.012. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. Sato K., Tsuchiya M., Saldanha J. et al. Reshaping a human antibody to inhibit the inerieukin-6-dependent tumor cell growth. Cancer Res, 1993;53:851-6. Aletaha D., Landewee R., Karonitsch T. et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthr Care Res 2008;59:1371-7. Guidance for Industry. Clinical Development Programs for drugs, devices, and biological products for the treatment of rheumatoid arthritis. (RA). UA. Food and Drug Administration. Center for drug evaluation and research, 1999. Mao Mao An, Zui Zou, Hei Shen et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010, on line. Nishimto N., Ito K., Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol, 2010, on line. Jones G., Sebba A., Gu J. et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis 2010;69:88-96. Maini R., Taylor P., Szechinski J. et al. Double-blind randomized controlled clinical trial of the interleukin 6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthr Rheum 2006;54:2817-29. Nishimoto N., Hashimoto J., Miasaka N. et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. Kremer J., Fleischmann R., Brzezicki J. et al. Tocilzumab inhibits structural joint damage, improved physical function, and increase DAS28 remission rates in RA patients who respond inadequately to methotrexate: the LITHE study. Ann Rheum Dis 2009; 68 (Suppl. 3):122(OP-0157). Smolen J., Beaulieu A., Rubbert-Roth A. et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet 2008;371:987-97. Emery P., Keystone E., Tony H.-P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-TNF biologics: results from a 24-week multicenter randomized placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23. Nishimoto N., Miyasaka N., Yamamoto K. et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-9. Genovese M.C., McKay J.D., Nasonov E.L. et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthr Rheum 2008;58:2968-80. Arnrett F.C., Edworth S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthr Rheum 1988;31:315-24. Fransen J., Stucki G., van Riel P.L.C.M. Rheumatoid arthritis measures. Arthr Rheum (Arthr Care Res) 2003;49:S214-S224. Smolen J.S., Churchill M., Rizzo W. et al. Tocilizumab treatment results in rapid improvements in the signs and symptoms to moderate-to-severe rheumatoid arthritis in four patients populations with different prior therapy exposure. Arthr Rheum 2008;58(Suppl.):S532(989). Hirabayashi Y., Ishii T., Harigae H. Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheum Int 2010, on line. Rubbert-Roth A., Braun J., Feast E. et al. Interim results of the TAMARA study -effectiveness and safety of the Interleukin-6 (IL-6) receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis (RA). ACR/ARHR, 2009, October 17-21, Philadelphia; P412. Bergman G.J., Hochberg M.C., Boers M. et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthr Rheum 2010, in press. Mima T., Nishimoto N. Clinical value of blocking IL-6 receptor. Curr Opin Rheumatol 2009;21:224-30.; https://rsp.mediar-press.net/rsp/article/view/1251

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1251
https://doi.org/10.14412/1995-4484-2010-1412

المؤلفون: N Iopichenok G, E Tsvetkova S, P Karusinov S, Yu Olyunin A, A. Smirnov V., Е Панасюк Ю

المصدر: Rheumatology Science and Practice; Vol 43, No 3 (2005); 195 ; Научно-практическая ревматология; Vol 43, No 3 (2005); 195 ; 1995-4492 ; 1995-4484 ; 10.14412/1995-4484-2005-3

Relation: https://rsp.mediar-press.net/rsp/article/view/1878

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/1878
https://doi.org/10.14412/1995-4484-2005-1068